Antibody-drug conjugates
Polyglycine linkers in antibody-drug conjugates address stability and aggregation issues, providing effective and efficient targeted drug delivery with improved in vivo efficacy.
Patent Information
- Application Number
- JP2026521765
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-10-17
- Filing Date
- 2024-10-16
- Publication Date
- 2026-11-19
AI Technical Summary
Existing antibody-drug conjugates face challenges with linker stability in plasma, leading to premature drug release and aggregation, which affects therapeutic efficacy and specificity.
The use of polyglycine linkers in antibody-drug conjugates for metal-free click or thiol ligation or transglutaminase-mediated transamidation, resulting in conjugates with low aggregation and improved conjugation efficiency.
The polyglycine linkers ensure stable delivery of drug payloads to targeted sites with negligible aggregation, enhancing in vivo efficacy and conjugation efficiency.
Smart Images

Figure 2026538973000001_ABST
Abstract
Description
[Technical Field]
[0001] The present invention relates to the field of antibody-drug conjugates, and more specifically to antibody-drug conjugates having a polyglycine linker. [Background technology]
[0002] Antibody-drug conjugates (ADCs) are essentially targeted delivery of active pharmaceutical drugs to selected specific cellular locations and represent a powerful approach for treating a wide range of diseases, offering many beneficial aspects compared to systemic delivery of the same drug.
[0003] In the field of ADCs, chemical linkers are typically used to attach pharmaceutical drugs to antibodies. These linkers must possess numerous important attributes, including the need for stability in plasma after prolonged drug administration. A stable linker allows for the localization of the ADC to a planned site or cell in the body and prevents premature release of the circulating payload, which would indiscriminately induce any undesirable biological responses, thereby reducing the therapeutic index of the ADC. Once internalized, the ADC should be processed to be effectively released so that the payload can bind to its target. [Overview of the project]
[0004] The inventors have surprisingly discovered that linkers containing polyglycine are highly suitable for metal-free click or thiol ligation or transglutaminase-mediated transamidation conjugation of drug payloads to antibodies, resulting in antibody-drug conjugates that exhibit no or negligible aggregation tendency. The resulting ADCs were found to exhibit remarkable in vivo efficacy. Thus, the inventors have for the first time been able to prepare an ADC with a payload that exhibits no aggregation whatsoever, while showing efficacy comparable to the most effective antibody-drug conjugates known to date, particularly the antibody-exatecan conjugate. Furthermore, the resulting ADCs were found to show improved conjugation efficiency.
[0005] The present invention relates, first and foremost, to an antibody-drug conjugate having structure (1), [ka] During the ceremony, AB is a cell-binding agent for antibodies, etc. n is an integer in the range of 5 to 8. L 1 However, it is a linker, L 2 However, it is a linker, L 3 However, it is a linker, a, b, and c are independently either 0 or 1. Is Z a conjugation group obtained by a metal-free click reaction, thiol ligation, or transglutaminase-mediated transamidation? Alternatively, Z is absent, a and b are 0, and the N-terminus of polyglycine is directly bound to AB in the absence of the saltase recognition sequence motif. D is the drug payload, This concerns antibody-drug conjugates where x is an integer in the range of 1 to 8.
[0006] The present invention further relates to a process for the synthesis of antibody-drug conjugates according to the present invention, linker-drug constructs suitable for use in the process according to the present invention, medical uses of antibody-drug conjugates according to the present invention, and pharmaceutical compositions comprising antibody-drug conjugates according to the present invention. [Modes for carrying out the invention]
[0007] definition The verb "includes" and its conjugations, when used herein and in the claims, are used in their non-restrictive sense to mean that the items following the word are included, but not excluded from items not specifically mentioned. Furthermore, references to elements with the indefinite articles "a" or "an" do not exclude the possibility of two or more of the elements being present, unless the context clearly requires the presence of only one of the elements. Thus, the indefinite articles "a" or "an" usually mean "at least one."
[0008] The compounds disclosed herein and in the claims may contain one or more chiral centers, and different diastereomers and / or enantiomers of the compounds may exist. Unless otherwise stated, the descriptions of any compound herein and in the claims are intended to include all diastereomers and mixtures thereof. Furthermore, unless otherwise stated, the descriptions of any compound herein and in the claims are intended to include individual enantiomers, as well as any mixtures, racemics, or otherwise of enantiomers. Where the structure of a compound is described as a particular enantiomer, it should be understood that the invention of this application is not limited to that particular enantiomer.
[0009] Compounds may arise in different tautomers. Unless otherwise stated, the compounds according to this invention are intended to include all tautomers. If the structure of a compound is described as a specific tautomer, it should be understood that the invention of this application is not limited to that specific tautomer.
[0010] The compounds disclosed herein and in the claims may further exist as R and S stereoisomers. Unless otherwise stated, any description of any compound herein and in the claims is intended to include both the individual R stereoisomers and individual S stereoisomers of the compound, as well as mixtures thereof. Where the structure of a compound is described as a particular S or R stereoisomer, it should be understood that the invention of this application is not limited to that particular S or R stereoisomer.
[0011] The compounds disclosed herein and in the claims may further exist as exo and endodiastereoisomers. Unless otherwise stated, any description of any compound herein and in the claims is intended to include both the individual exodiastereoisomers and individual endodiastereoisomers of the compound, as well as mixtures thereof. Where the structure of a compound is described as a particular endo or exodastereomer, it should be understood that the invention of this application is not limited to that particular endo or exodastereomer.
[0012] Compounds according to the present invention may exist in the form of salts, which are also encompassed by the present invention. A salt is typically a pharmaceutically acceptable salt containing a pharmaceutically acceptable anion. The term “its salt” means a compound formed when an acidic proton, typically a proton of an acid, is replaced by a cation such as a metal cation or an organic cation. Where applicable, a salt is a pharmaceutically acceptable salt, but this is not required for salts not intended for administration to a patient. For example, in a salt of a compound, the compound may be protonated with an inorganic or organic acid to form a cation with a conjugate base of the inorganic or organic acid as an anionic component of the salt.
[0013] The term "pharmaceutically acceptable" salt means a salt that is acceptable for administration to a patient, such as a mammal (a salt having a counterion that is mammalian safe for a given drug regimen). Such salts may be derived from pharmaceutically acceptable inorganic or organic bases, and pharmaceutically acceptable inorganic or organic acids. "pharmaceutically acceptable salt" refers to a pharmaceutically acceptable salt of a compound, which may be derived from a variety of organic and inorganic counterions known in the art, such as sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, etc., and if the molecule contains a basic functional group, it may also include salts of organic or inorganic acids, such as hydrochloride, hydrobromide, formate, tartrate, besylate, mesylate, acetate, maleate, oxalate, etc.
[0014] The term "protein" is used herein in its usual scientific sense. Herein, a polypeptide containing approximately 10 or more amino acids is considered a protein. Proteins may contain naturally occurring amino acids, but may also contain non-natural amino acids.
[0015] The term “antibody” is used herein in its ordinary scientific sense. An antibody is a protein produced by the immune system that can recognize and bind to a specific antigen. An antibody is an example of a glycoprotein. The term “antibody” as used herein is used in its broadest sense and specifically includes monoclonal antibodies, polyclonal antibodies, dimers, multimers, multispecific antibodies (e.g., bispecific antibodies), antibody fragments, and double-chain and single-chain antibodies. The term “antibody” as used herein is also intended to include human antibodies, humanized antibodies, chimeric antibodies, and antibodies that specifically bind to cancer antigens. The term “antibody” is also intended to include antigen-binding fragments of antibodies as well as whole immunoglobulins. Furthermore, the term includes genetically engineered antibodies and derivatives of antibodies. Antibodies, antibody fragments, and genetically engineered antibodies can be obtained by methods known in the art.
[0016] "Antibody fragment" is defined herein as a portion of an intact antibody that comprises the antigen-binding region or variable region thereof. Examples of antibody fragments include Fab, Fab', F(ab')2, and Fv fragments, diabodies, minibodies, triabodies, tetrabodies, linear antibodies, single-chain antibody molecules, scFv, scFv-Fc, multispecific antibody fragments formed from antibody fragments, fragments produced by a Fab expression library, or epitope-binding fragments of any of the above that immunospecifically bind to a target antigen (e.g., a cancer cell antigen, a viral antigen, or a microbial antigen).
[0017] "Antigen" is defined herein as an entity to which an antibody specifically binds.
[0018] The terms "specific binding" and "specifically binds" are defined herein as a highly selective manner in which an antibody binds to the epitope of its corresponding target antigen and does not bind to numerous other antigens. Typically, the antibody or antibody derivative has at least about 1×10 -7 M, preferably 10 -8 M to 10 -9 M, 10 -10 M, 10 -11 M, or 10 -12 M, and binds to the given antigen with an affinity that is at least two times greater than its affinity for binding to a non-specific antigen (e.g., BSA, casein) other than the given antigen or a closely related antigen.
[0019] The term "substantial" or "substantially" is defined herein as the majority of a mixture or sample, i.e., a population of more than 50%, preferably more than 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%.
[0020] In this specification, a "linker" is defined as a portion that connects two or more elements of a compound. For example, in an antibody conjugate, the antibody and the payload are covalently bonded to each other via a linker. A linker may include one or more linkers and spacer portions that connect various parts within the linker.
[0021] A “spacer” or spacer portion is defined herein as a portion that separates (i.e., provides distance between) two (or more) portions of a linker and covalently bonds them together. A linker may be part of, for example, a linker construct, a linker conjugate, or a bioconjugate, as defined below.
[0022] In this specification, a “self-sacrificing group” is defined as part of a linker in a functional antibody-drug conjugate, which is used to conditionally release a free drug at a site targeted by a ligand unit.
[0023] The activatable self-sacrificial moiety includes an activatable group (AG) and a self-sacrificial spacer unit. For example, activation of the activatable group by enzymatic conversion of an amide group to an amino group, or by reduction of a disulfide to a free thiol group, initiates a self-sacrificial reaction sequence that results in the release of a free drug by one or more of various mechanisms, which may involve (transient) 1,6-removal of a p-aminobenzyl group to a p-quinone methide, and optionally, the release of carbon dioxide and / or a subsequent second cyclization-release mechanism. The self-sacrificial aggregate unit may be part of a chemical spacer that connects the antibody and payload (via a functional group). Alternatively, the self-sacrificial group may branch off from the chemical spacer that connects the antibody and payload, rather than being an intrinsic part of the chemical spacer.
[0024] "Cathepsin-cleavable peptide" is defined herein as a peptide moiety in which the peptide bond can be cleaved via a process of proteolysis mediated by one or more proteases selected from the cathepsin family of proteases, specifically cathepsin B and / or cathepsin D, particularly cathepsin B.
[0025] "Regmine-cleavable peptide" is defined herein as a peptide moiety in which the peptide bond can be cleaved via a proteolytic process mediated by cysteine legmine (asparagine endopeptidase).
[0026] In this specification, "conjugate" is defined as a compound in which an antibody is covalently bound to a payload via a linker. A conjugate comprises one or more antibodies and / or one or more payloads.
[0027] The term "payload" refers to the portion that covalently binds to the target site, such as an antibody, but also to the molecules released from the conjugate upon uptake and / or cleavage of the linker. Therefore, the payload refers to a monovalent portion with one open end that covalently binds to the target site via the linker, and also to the molecules released from it.
[0028] In this specification, the term "hydrophobic drug" means a clogP value greater than 3 (the calculated logarithm of its partition coefficient between n-octanol and water, logarithm (c オクタノール / c 水 It is defined as a drug having )). The cLogP value can be estimated using CDD Vault software (Collaborative Drug Discovery Inc.) based on the method described in Gedeck et al., 2017, J. Chem. Inf. Model. 57, 8, 1847-1858. Model training information using publicly available datasets is available from CDD.
[0029] Aggregation is the process by which molecules self-associate with each other. In the context of this invention, the level of aggregation is evaluated during the conjugation of a linker construct into an antibody. During conjugation, aggregation is quantified in terms of monomer content percentage. Higher monomer value percentages typically correspond to lower levels of aggregation. Monomer value percentages of 93%, 95%, or higher typically mean negligible levels of aggregation or no aggregation at all, while values below this threshold are typically interpreted as higher levels of aggregation.
[0030] explanation The inventors have developed an antibody-drug conjugate comprising a payload and a novel polyglycine linker system, which exhibits a low to negligible aggregation tendency. In particular, when the payload is a hydrophobic drug, the polyglycine linker system results in an ADC with increased hydrophilicity, consequently leading to a low to negligible aggregation tendency. The resulting ADC was found to exhibit remarkable in vivo efficacy. Furthermore, the resulting ADC was found to show improved conjugation efficiency.
[0031] The present invention relates, first and foremost, to antibody-drug conjugates. In a second aspect, the present invention relates to a process for the synthesis of antibody-drug conjugates according to the present invention. In a third aspect, the present invention relates to linker-drug constructs suitable for use in the process according to the present invention. In a fourth aspect, the present invention relates to the medical use of antibody-drug conjugates according to the present invention, and pharmaceutical compositions comprising antibody-drug conjugates according to the present invention. Those skilled in the art will understand that all aspects are relevant, and that everything described with respect to antibody-drug conjugates according to the present invention applies equally to the process according to the present invention, the linker-drug constructs according to the present invention, the uses according to the present invention, and the compositions according to the present invention, and vice versa.
[0032] The present invention can be defined according to the following list of preferred embodiments. The present invention relates to an antibody-drug conjugate having structure (1), [ka] During the ceremony, AB is a cell-binding agent for antibodies, etc. n is an integer in the range of 5 to 8. L 1 However, it is a linker, L 2 However, it is a linker, L 3 However, it is a linker, a, b, and c are independently either 0 or 1. Is Z a conjugation group obtained by a metal-free click reaction, thiol ligation, or transglutaminase-mediated transamidation? Alternatively, Z is absent, a and b are 0, and the N-terminus of polyglycine is directly bound to AB in the absence of the saltase recognition sequence motif. D is the drug payload, The present invention provides an antibody-drug conjugate in which x is an integer in the range of 1 to 8.
[0033] In one embodiment, n is 5, 6, or 7. In a further embodiment, n is 5 or 6. In yet another embodiment, n is 5.
[0034] In one embodiment, the present invention is L 3 The present invention provides an antibody-drug conjugate comprising a cathepsin-cleavable peptide or a legmine-cleavable peptide, particularly a cathepsin-cleavable peptide.
[0035] In one embodiment, the present invention is L 3 but, [ka] It has structure (1a), [ka] During the ceremony, AB is a cell-binding agent for antibodies, etc. n is an integer in the range of 5 to 8. L 1 However, it is a linker, L 2 However, it is a linker, L 3a However, it is a linker, a, b, and d are independently either 0 or 1. Is Z a conjugation group obtained by a metal-free click reaction, thiol ligation, or transglutaminase-mediated transamidation? Alternatively, Z is absent, a and b are 0, and the N-terminus of polyglycine is directly conjugated to AB in the absence of the saltase recognition sequence motif. D is the drug payload, p is an integer in the range of 1 to 5. Each R 11 However, independently, they are amino acid side chains, The present invention provides an antibody-drug conjugate in which x is an integer in the range of 1 to 8.
[0036] In one embodiment, the present invention relates to a peptide (NH-CR 11Each occurrence of -CO)p is Val-Cit, Glu-Val-Cit, Val-Ala, Val-Lys, Val-Arg, Aclys-Val-Cit, Aclys-Val-Ala, Glu-Val -Ala, Asp-Val-Ala, Phe-Gly, Phe-Cit, Phe-Ala, Phe-Lys, Phe-Arg, Ala-Lys, Leu-Cit, Ile-Cit, Trp-Cit, A The present invention provides antibody-drug conjugates selected from la-Ala-Asn, Ala-Asn, Asn-Asn, and Lys, particularly Val-Cit, Glu-Val-Cit, Val-Ala, Glu-Val-Ala, Val-Lys, Phe-Gly, Phe-Cit, Phe-Ala, Phe-Lys, Ala-Ala-Asn, most specifically Val-Cit or Val-Ala.
[0037] In one embodiment, p is 2 or 3, particularly 2. In a further embodiment, p is 2 or 3, particularly 2, and n is 5.
[0038] In one embodiment, d is 0. In a further embodiment, d is 0 and p is 2 or 3, particularly 2. In yet another embodiment, d is 0, p is 2 or 3, particularly 2, and n is 5. In one embodiment, the present invention is L 3 The present invention provides an antibody-drug conjugate comprising a self-sacrificing group. In further embodiments, L 3 It contains an activatable self-sacrificing group.
[0039] In further embodiments, the self-sacrificing group is a para-aminobenzyloxycarbonyl (PABC) derivative.
[0040] Para-aminobenzyloxycarbonyl (PABC) derivatives have a general structure (L 4 ) can be represented by, [ka] During the ceremony, A is a 5 or 6-membered aromatic or heteroaromatic ring that is optionally substituted. R 21 H, R 22 , C(O)OH, and C(O)R 22 Selected from, R 22 C1-C 24 (hetero)alkyl groups, C3-C 10 (hetero)cycloalkyl groups, C2-C 10 (hetero)aryl group, C3-C 10 Alkyl(hetero)aryl groups and C3-C 10 It is a (hetero)arylalkyl group, and the group is optionally substituted with O, S, and NR 23 Optionally interrupted by one or more heteroatoms selected from R 23 These are independently selected from the group consisting of hydrogen and C1-C4 alkyl groups.
[0041] In a further embodiment, the self-sacrificing group is an activatable self-sacrificing moiety, and A is substituted with an activatable group (AG). In yet another embodiment, AG is [ka] Selected from, in the formula, Each R 31 R is independently selected from hydrogen and acetyl. 32 This is hydrogen or a C1-C6 alkyl group.
[0042] In one embodiment, A is optionally substituted phenyl, particularly optionally substituted 1,4-phenyl.
[0043] In particular, the self-sacrificing group is an activatable self-sacrificing moiety, A is a phenyl substituted with an activatable group (AG), and the para-aminobenzyloxycarbonyl (PABC) derivative has a general structure (L 4a ) can be represented by, [ka] In the formula, AG and R21 This may be as described in any part of this specification.
[0044] In one embodiment, L 3 is a general structure (L 4 ) or (L 4a It is a para-aminobenzyloxycarbonyl (PABC) derivative represented by ), and contains a self-sacrificing group.
[0045] In a particular embodiment, L 3 is a general structure (L 4 ) or (L 4a It is a self-sacrificing group, which is a para-aminobenzyloxycarbonyl (PABC) derivative represented by ).
[0046] In one embodiment, L 3a is a general structure (L 4 ) or (L 4a It is a self-sacrificing group, which is a para-aminobenzyloxycarbonyl (PABC) derivative represented by ).
[0047] In one embodiment, the present invention relates to an antibody-drug conjugate having structure (1b), [ka] During the ceremony, AB is a cell-binding agent for antibodies, etc. n is an integer in the range of 5 to 8. L 1 However, it is a linker, L 2 However, it is a linker, a and b are independently 0 or 1. Is Z a conjugation group obtained by a metal-free click reaction, thiol ligation, or transglutaminase-mediated transamidation? Alternatively, Z is absent, a and b are 0, and the N-terminus of polyglycine is directly bound to AB in the absence of the saltase recognition sequence motif. D is the drug payload, p is an integer in the range of 0 to 5. Each R 11 However, independently, they are amino acid side chains, A is a 5 or 6-membered, aromatic or heteroaromatic ring that has been optionally substituted. R 21 However, H, R 22 , C(O)OH, and C(O)R 22 Selected from, R 22 However, C1-C 24 (hetero)alkyl groups, C3-C 10 (hetero)cycloalkyl groups, C2-C 10 (hetero)aryl group, C3-C 10 Alkyl(hetero)aryl groups and C3-C 10 (Hetero)arylalkyl groups, wherein the group is optionally substituted with O, S, and NR 23 Optionally interrupted by one or more heteroatoms selected from R 23 However, independently selected from the group consisting of hydrogen and C1-C4 alkyl groups, The present invention provides an antibody-drug conjugate in which x is an integer in the range of 1 to 8.
[0048] In one embodiment, a is 0, and the conjugation site is a cysteine residue, which is optionally naturally present in the antibody after reduction of the disulfide bond, or the cysteine residue is manipulated by amino acid substitution with cysteine, cysteine insertion, or introduction of a single cysteine residue or a peptide fragment containing a cysteine residue at the N-terminus or C-terminus.
[0049] In an alternative embodiment, a is 0, and the conjugation site is a glutamine residue, particularly one that is naturally present in the antibody, or the glutamine residue is manipulated by, preferably, amino acid substitution with glutamine, glutamine insertion, or introduction of a single glutamine residue or a peptide fragment containing a glutamine residue at the N-terminus or C-terminus.
[0050] In one embodiment, the antibody-drug conjugate has structure (1c), [ka] Z, L 2 , L 3 D, b, c, n, and x are as defined herein, e is an integer in the range of 0 to 20. Su is a monosaccharide, G is the monosaccharide portion, GlcNAc is the N-acetylglucosamine portion, Fuc is the fucose portion, m is either 0 or 1.
[0051] In one embodiment, the antibody-drug conjugate has structure (1d), [ka] Z, L 2 , L 3 D, b, c, n, and x are as defined herein, L 1 is -NH-L 5 and L 5 is a linker
[0052] An antibody-drug conjugate according to any one of the prior embodiments, wherein the drug payload is a hydrophobic drug.
[0053] The antibody-drug conjugate according to any one of the prior embodiments, wherein the drug payload is camptothecin or a derivative thereof, for example, exatecan or a derivative thereof, for example, exatecan or deruxtecan, in particular exatecan.
[0054] In particular, D is exatecan, and the drug linker is cleaved under cellular conditions, resulting in the following equation (D 1 It can release exatecan having ) [ka]
[0055] In another aspect, the present invention relates to a process for synthesizing the antibody-drug conjugate of the present invention, wherein the process is (i) Structure AB-((L 1 ) a -F)x modified antibody, in the formula, AB is an antibody, L 1 However, it is a linker, a is 0 or 1, F is a click probe that can react with Q in a metal-free click reaction, or a thiol or its precursor, or an acyl donor that can react with Q in transglutaminase-mediated transamidation. A modified antibody in which x is an integer in the range of 1 to 8. (ii) A linker-drug construct according to structure (5), [ka] During the ceremony, Q is a click probe capable of performing a metal-free click reaction, or a thiol-reactive probe, or an acyl-acceptor probe capable of reacting with acyl donor F in transglutaminase-mediated transamidation. L 2 , L 3 The linker-drug constructs are reacted, where D, n, b, and c are as defined herein. The present invention provides a process comprising forming an antibody-drug conjugate, wherein the drug covalently binds to the antibody via a conjugate group Z formed by a metal-free click reaction between Q and F, or by thiol ligation between Q and F, or by transglutaminase-mediated transamidation between Q and F.
[0056] In one embodiment, the click probe Q includes a cyclic alkyne moiety, a cyclic alkene moiety, or a tetrazine moiety, or the thiol-reactive probe Q includes a maleimide moiety.
[0057] In one embodiment, the click probe Q is selected from the group consisting of optionally substituted (hetero)cyclopropenyl groups, (hetero)cyclobutenyl groups, trans-(hetero)cycloheptenyl groups, trans-(hetero)cyclooctenyl groups, trans-(hetero)cyclononenyl groups, or trans-(hetero)cyclodecynyl groups.
[0058] In one embodiment, the acyl acceptor probe Q is selected from amines such as primary amines, hydrazines, hydrazides, alkoxyamines, or aryloxyamines. In further embodiments, the amine, hydrazine, hydrazide, or oxyamine is an aryl derivative, particularly an optionally substituted phenyl or optionally substituted benzyl derivative, such as optionally substituted phenylhydrazine. In one embodiment, the acyl acceptor is a hydrazine or hydrazide. In one embodiment, the acyl acceptor is a hydrazide or an optionally substituted arylhydrazine derivative. In further embodiments, the acyl acceptor is an optionally substituted arylhydrazine derivative or an optionally substituted arylhydrazide derivative. In yet another embodiment, the acyl acceptor is an optionally substituted phenylhydrazine or an optionally substituted phenylhydrazide derivative.
[0059] In one embodiment, the click probe F is selected from the group consisting of azides, tetrazines, triazines, nitrones, nitrile oxides, nitrile imines, diazo compounds, ortho-quinones, dioxothiophenes, cydonones, and cyclic alkene moieties, and preferably, the click probe F is an azide moiety.
[0060] In one embodiment, the click reaction is a 1,3-dipolar cycloaddition or a (4+2) cycloaddition, in the process of the present invention.
[0061] In one embodiment, F is a thiol.
[0062] In one embodiment, thiol ligation is a nucleophilic reaction, preferably Michael addition or nucleophilic substitution.
[0063] In one embodiment, a is 0, and the conjugation site is a cysteine residue, which is optionally naturally present in the antibody after reduction of the disulfide bond, or the cysteine residue is manipulated by amino acid substitution with cysteine, cysteine insertion, or introduction of a single cysteine residue or a peptide fragment containing a cysteine residue at the N-terminus or C-terminus.
[0064] In one embodiment, the click probe F is selected from the group consisting of azides, tetrazines, triazines, nitrones, nitrile oxides, nitrile imines, diazo compounds, ortho-quinones, dioxothiophenes, cydonones, and cyclic alkene moieties, in particular, the click probe F is an azide moiety and / or the click reaction is a 1,3-dipolar cycloaddition or a (4+2) cycloaddition, or F is a thiol and / or the thiol ligation is a Michael addition or nucleophilic substitution.
[0065] In an alternative embodiment, F is an acyl donor that can react with acyl acceptor probe Q in transglutaminase-mediated transamidation. F is an acyl derivative, particularly an amide or carboxylic acid derivative, where the acyl group is located in the side chain of an amino acid residue. In particular, the amino acid is glutamine. Specifically, a is 0, and the amino acid, particularly glutamine, is present in antibody AB.
[0066] In one embodiment, a is 0, and the conjugation site is a glutamine residue, which is either naturally present in the antibody or is manipulated by, preferably, amino acid substitution with glutamine, glutamine insertion, or introduction of a single glutamine residue or a peptide fragment containing a glutamine residue at the N-terminus or C-terminus.
[0067] In one embodiment of the process of the present invention, AB-((L 1 )aF)x is due to structure (6), [ka] In the formula, F and x are defined herein, e is an integer in the range of 0 to 10. Su is a monosaccharide, G is the monosaccharide portion, GlcNAc is the N-acetylglucosamine portion, Fuc is the fucose portion, m is either 0 or 1.
[0068] In one embodiment of the process of the present invention, AB-((L 1 )aF)x is due to structure (7), [ka] In the formula, F and x are as defined herein, L 1 is -NH-L 5 That is the case.
[0069] In one embodiment, L 1 is -NH-NH-L 5 ' and especially L 1 is -NH-NH-C(O)-L 5 ''
[0070] In one embodiment, L 1 is -NH-L 5Therefore, F is a click probe capable of performing a metal-free click reaction.
[0071] In one embodiment, -NH-L 5 The terminal NH group is conjugated to a glutamine residue in the antibody.
[0072] In one embodiment, the process of the present invention involves transglutaminase, particularly microbial transglutaminase-mediated transamidation, which converts H2N-L 5 The process further includes the step of preparing an antibody-linker construct of structure 7 by conjugating -F to an antibody.
[0073] In another aspect, the present invention relates to a linker-drug construct of structure (5), [ka] During the ceremony, Q is a click probe capable of performing a metal-free click reaction, or a thiol-reactive probe, or an acyl-acceptor probe capable of reacting with acyl donor F in transglutaminase-mediated transamidation. L 2 , L 3 The present invention provides a linker-drug construct in which D, n, b, and c are as defined herein.
[0074] In one embodiment, the click probe Q includes a cyclic alkyne moiety or a cyclic alkene moiety, or the thiol-reactive probe Q includes a maleimide moiety.
[0075] In one embodiment, the click probe Q includes an annular alkyne portion or an annular alkene portion. In one embodiment, the click probe Q includes a tetrazine portion. In one embodiment, the click probe Q is selected from the group consisting of optionally substituted (hetero)cyclopropenyl groups, (hetero)cyclobutenyl groups, trans-(hetero)cycloheptenyl groups, trans-(hetero)cyclooctenyl groups, trans-(hetero)cyclononenyl groups, or trans-(hetero)cyclodecynyl groups.
[0076] In another aspect, the present invention provides a pharmaceutical composition comprising the antibody-drug conjugate of the present invention and a pharmaceutically acceptable carrier.
[0077] In another aspect, the present invention provides the antibody-drug conjugate of the present invention for use in the treatment of a subject in need of the treatment.
[0078] In another aspect, the present invention provides the antibody-drug conjugate of the present invention for use in the treatment of cancer.
[0079] In another aspect, the present invention provides the antibody-drug conjugate for use according to the present invention, wherein the cancer is HER2-positive cancer, preferably breast cancer, gastric cancer, colon cancer, lung cancer, pancreatic cancer, urothelial cancer, brain cancer, or ovarian cancer.
[0080] Antibody-drug conjugate
[0081] The antibody-drug conjugate according to the present invention has the structure (1),
Chemical Formula
[0082] The conjugate according to the present invention comprises a polyglycine (Gly)n linker, where n is an integer in the range of 5 to 8. The conjugate according to the present invention may comprise a self-sacrificing group and / or a cleavable linker, and in particular may comprise a peptide spacer and / or a para-aminobenzyloxycarbonyl (PABC) moiety or a derivative thereof.
[0083] In particular, n is 5, 6, or 7, more specifically, n is 5 or 6, and most specifically, n is 5.
[0084] In particular, the antibody-drug conjugate of the present invention contains a cathepsin-cleavable peptide.
[0085] The peptide spacer is (NH-CR 11 -CO)p is defined by the formula, where R 11represents an amino acid side chain known in the art. As used herein, an amino acid may be a natural amino acid or a synthetic amino acid. In particular, all amino acids are in their L configuration. p is an integer in the range of 1 to 5, particularly in the range of 2 to 5. Accordingly, the peptide spacer comprises 1 to 5 amino acids. In particular, the peptide is a dipeptide (p=2) or a tripeptide (p=3), and most preferably, the peptide spacer is a dipeptide. Although any peptide spacer may be used, in particular, the peptide spacer is selected from Val-Cit, Glu-Val-Cit, Val-Ala, Val-Lys, Val-Arg, AcLys-Val-Cit, AcLys-Val-Ala, Glu-Val-Ala, Asp-Val-Ala, Phe-Gly, Phe-Cit, Phe-Ala, Phe-Lys, Phe-Arg, Ala-Lys, Leu-Cit, Ile-Cit, Trp-Cit, Ala-Ala-Asn, Asn-Asn, Ala-Asn, and Lys, preferably Val-Cit, Glu-Val-Cit, Val-Ala, Glu-Val-Ala, Val-Lys, Phe-Gly, Phe-Cit, Phe-Ala, Phe-Lys, Ala-Ala-Asn, most preferably Val-Cit or Val-Ala. In one embodiment, the peptide spacer is Val-Cit. In another embodiment, the peptide spacer is Val-Ala.
[0086] In one embodiment, the peptide spacer and the polyglycine linker (Gly) n form an adjacent, uninterrupted polypeptide. In one embodiment, this uninterrupted polypeptide comprises the peptide sequence Gly-Gly-Phe-Gly (GGFG) at its C-terminus or N-terminus.
[0087] In one embodiment, L 3 has the structure L 3’ ,
Chemical Formula
[0088] In particular, R 11 The side chains are selected from alanine, cysteine, aspartic acid, glutamic acid, phenylalanine, glycine, histidine, isoleucine, lysine, acetyllysine, leucine, methionine, asparagine, pyrrolidine, proline, glutamine, arginine, serine, threonine, selenocysteine, valine, tryptophan, tyrosine, and citrulline. The specific amino acid side chains are those of Val, Cit, Ala, Lys, Arg, AcLys, Phe, Leu, Ile, Trp, Glu, Asp, and Asn, more preferably from the side chains of Val, Cit, Ala, Glu, and Lys. In other words, R 11 Preferably, it is selected from CH3(Ala), CH2CH(CH3)2(Leu), CH2CH2CH2NHC(O)NH2(Cit), CH2CH2CH2CH2NH2(Lys), CH2CH2CH2NHC(O)CH3(AcLys), CH2CH2CH2NHC(=NH)NH2(Arg), CH2Ph(Phe), CH(CH3)2(Val), CH(CH3)CH2CH3(Ile), CH2C(O)NH2(Asn), CH2CH2C(O)OH(Glu), CH2C(O)OH(Asp), and CH2(1H-indole-3-yl)(Trp). 11 The most specific embodiments are CH3(Ala), CH2CH2CH2NHC(O)NH2(Cit), CH2CH2CH2CH2NH2(Lys), CH2CH2C(O)OH(Glu), and CH(CH3)2(Val). Most specifically, R 11 These are CH3(Ala), CH2CH2CH2NHC(O)NH2(Cit), CH2CH2CH2CH2NH2(Lys), or CH(CH3)2(Val).
[0089] In particular, peptide spacers have a general structure (L 3b ) can be represented by, [ka] In the formula, R 11 This is as defined above, and especially R 11 This is CH3(Ala) or CH2CH2CH2NHC(O)NH2(Cit).
[0090] The wavy line indicates a connection to the rest of the conjugate.
[0091] In particular, p is 2, and more specifically, p is 2 and n is 5.
[0092] In one embodiment, the present invention relates to an antibody-drug conjugate having structure (1a), [ka] During the ceremony, AB is a cell-binding agent for antibodies, etc. n is an integer in the range of 5 to 8. L 1 However, it is a linker, L 2 However, it is a linker, L 3a However, it is a linker, a, b, and d are independently either 0 or 1. Is Z a conjugation group obtained by a metal-free click reaction, thiol ligation, or transglutaminase-mediated transamidation? Alternatively, Z is absent, a and b are 0, and the N-terminus of polyglycine is directly conjugated to AB in the absence of the saltase recognition sequence motif. D is the drug payload, p is an integer in the range of 1 to 5. Each R 11 However, independently, they are amino acid side chains, The present invention provides an antibody-drug conjugate in which x is an integer in the range of 1 to 8.
[0093] L 3 The antibody-drug conjugate of the present invention may contain a self-sacrificing group, in particular an activatable self-sacrificing group.
[0094] In particular, the self-sacrificing group is a para-aminobenzyloxycarbonyl (PABC) derivative.
[0095] Para-aminobenzyloxycarbonyl (PABC) derivatives have a general structure (L 4 ) can be represented by, [ka] During the ceremony, A is a 5 or 6-membered aromatic or heteroaromatic ring that is optionally substituted. R 21 H, R 22 , C(O)OH, and C(O)R 22 Selected from, R 22 C1-C 24 (hetero)alkyl group, C3-C 10 (hetero)cycloalkyl groups, C2-C 10 (hetero)aryl group, C3-C 10 Alkyl(hetero)aryl groups and C3-C 10 It is a (hetero)arylalkyl group, and the group is optionally substituted with O, S, and NR 23 Optionally interrupted by one or more heteroatoms selected from R 23 These are independently selected from the group consisting of hydrogen and C1-C4 alkyl groups.
[0096] The wavy line indicates a connection to the rest of the conjugate.
[0097] Preferred five-membered rings are oxazole, thiazole, and furan. Preferred six-membered rings are phenyl and pyridyl. In particular, A is optionally substituted with 1,4-phenyl, 2,5-pyridyl, or 3,6-pyridyl. Most specifically, A is 1,4-phenyl.
[0098] In particular, the self-sacrificing group is an activatable self-sacrificing moiety, and A is substituted by an activatable group (AG). More specifically, AG is [ka] Selected from, in the formula, Each R 31 R is independently selected from hydrogen and acetyl. 32 This is hydrogen or a C1-C6 alkyl group.
[0099] The wavy line indicates a connection to A.
[0100] In particular, R 31 and R 32 It is hydrogen.
[0101] In particular, the self-sacrificing group is an activatable self-sacrificing moiety, A is a phenyl substituted with an activatable group (AG), and the para-aminobenzyloxycarbonyl (PABC) derivative has a general structure (L 4a ) can be represented by, [ka] In the formula, AG and R 21 This may be as described in any part of this specification.
[0102] In particular, the antibody-drug conjugate of the present invention having structure (1b), [ka] During the ceremony, AB is an antibody, n is an integer in the range of 5 to 8. L 1 However, it is a linker, L 2 However, it is a linker, L 3a However, it is a linker, a and b are independently 0 or 1. Is Z a conjugation group obtained by a metal-free click reaction, thiol ligation, or transglutaminase-mediated transamidation? Alternatively, Z is absent, a and b are 0, and the N-terminus of polyglycine is directly bound to AB in the absence of the saltase recognition sequence motif. D is the drug payload, p is an integer in the range of 0 to 5. Each R 11 However, independently, they are amino acid side chains, A is a 5 or 6-membered, aromatic or heteroaromatic ring that has been optionally substituted. R 21 However, H, R 22 , C(O)OH, and C(O)R 22 Selected from, R 22が , C1-C 24 (hetero)alkyl group, C3-C 10 (hetero)cycloalkyl groups, C2-C 10 (hetero)aryl group, C3-C 10 Alkyl(hetero)aryl groups and C3-C 10 (Hetero)arylalkyl groups, wherein the group is optionally substituted with O, S, and NR 23 Optionally interrupted by one or more heteroatoms selected from R 23 However, independently selected from the group consisting of hydrogen and C1-C4 alkyl groups, The antibody-drug conjugate of the present invention, wherein x is an integer in the range of 1 to 8.
[0103] Preferred five-membered rings are oxazoles, thiazoles, and furans. Preferred six-membered rings are phenyl and pyridyl. In particular, A is optionally substituted 1,4-phenyl, 2,5-pyridyl, or 3,6-pyridyl. Most specifically, A is 1,4-phenyl. In particular, when phenyl is substituted with the activatable group AG, A is the general structure (L 4aIn the context of para-aminobenzyloxycarbonyl (PABC) derivatives represented by ), this is 1,3,4-phenyl as defined above.
[0104] In particular, R 21 is H or C(O)R 22 And in the formula, R 22 is 4-methylpiperazine or morpholine. In particular, R 21 H is
[0105] Linker (L 1 , L 2 , L 3 , and L3 a ) Linkers, also known as linking units, are well known in the art and any suitable linker can be used. In the context of the present invention, the payload is linker L 3 via polyglycine linker (Gly) n Chemically connected, the polyglycine linker (Gly)n is linked to linker L 2 The linker L is chemically attached to the connecting group Z, which is obtained via a metal-free click reaction or thiol ligation, or by transglutaminase-mediated transamidation, and the connecting group Z is linked to the linker L 1 It is chemically connected to the antibody via a linker, particularly linker L. 2 This may include one or more branching points for attaching multiple payloads to a single connector.
[0106] Linker L 1 It may exist (a=1) or it may not exist (a=0). Linker L 1 If it is not present, click probe F is directly attached to the antibody.
[0107] Typically, if the conjugation is via thiol ligation, a is 0. Typically, if the conjugation is via a click reaction, a is 1.
[0108] If Z does not exist, a is 0, and b is 0, then polyglycine linker (Gly) n The N-terminus of this molecule is directly bound to antibodies, for example, via transglutaminase, particularly microbial transglutaminase (MTGase) conjugation, in the absence of the saltase recognition sequence motif.
[0109] Linkers are, for example, straight-chain or branched C1-C 200 Alkylene group, C2-C 200 Alkenylene group, C2-C 200 Alkynylene group, C3-C 200 Cycloalkylene group, C5-C 200 Cycloalkenylene group, C8-C 200 Cycloalkylene group, C7-C 200 Alkyl arylene group, C7-C 200 Arylalkylene group, C8-C 200 Arylalkenylene group, C9-C 200 The group can be selected from the group consisting of arylalkylene groups.Optionally, alkylene groups, alkenylene groups, alkylylene groups, cycloalkylene groups, cycloalkenylene groups, cycloalkylene groups, alkylarylene groups, arylalkylene groups, arylalkenylene groups, and arylalkylene groups may be substituted, and optionally, the group may be interrupted by one or more heteroatoms, preferably 1 to 100 heteroatoms, the heteroatoms preferably O, S(O)y, and NR 12 Selected from the group consisting of, where y is 0, 1, or 2, preferably y is 2, R 12 These are independently hydrogen, halogen, and C1-C 24 Alkyl alkyl group, C8-C 24 (hetero)aryl group, C1-C 24 Alkyl (hetero)aryl group, and C1-C 24 Selected from the group consisting of (hetero)arylalkyl groups.
[0110] In particular, L 2 It does not contain (poly)ethylene glycol linker. In particular, L 3If present, it does not contain polyethylene glycol linker. In particular, L 2 L 3 Also, if present, it does not contain polyethylene glycol linker.
[0111] In particular, L 2 For example, -(CR 1 R 2 )y-,-(CR 1 R 2 )yC(O)-, and -C(O)-(CR 1 R 2 ) is selected from C(O)-, where y is an integer in the range of 0 to 6, and one or more CRs. 1 R 2 , NR 1 It can be replaced by any choice, R 1 and R 2 H and R are independent of each other. 2a , C(O)OH, and C(O)R 2a Selected from, R 2a These are C1-C6 (hetero)alkyl groups, C3-C 10 (hetero)cycloalkyl groups, C6-C 10 (hetero)aryl group, C7-C 14 Alkyl (hetero)aryl group, and C7-C 14 Selected from (hetero)arylalkyl groups.
[0112] In particular, R 1 and R 2 H is H.
[0113] In one embodiment, L 2 is, -(CH2) 1-5 -C(O)-. In certain embodiments, L 2 This is -CH2C(O)- or -CH2CH2C(O)-.
[0114] In one embodiment, L 2 is -C(O)-(CH2) 1-5 -C(O)-. In certain embodiments, L 2This is -C(O)(CH2)2C(O)- or -C(O)(CH2)4C(O)-.
[0115] Branching section In one embodiment, the linker of the conjugate according to the present invention includes a branched portion. In the context of the present invention, “branched portion” refers to a portion embedded in the linker that connects three parts. In other words, the branched portion includes at least three bindings to the other parts, typically one binding to antibody AB connected to Z, one binding to the payload, and one binding to a second payload. The branched portion is preferably on linker L 2 It is embedded in. Any portion containing at least three bonds to other portions is suitable as a branched portion in the context of the present invention. In preferred embodiments, the branched portion BM is selected from a carbon atom, a nitrogen atom, a phosphorus atom, a (hetero)aromatic ring, a (hetero)ring, or a polycyclic portion. Most preferably, the branched portion is a nitrogen atom.
[0116] In one embodiment, linker L 2 It includes a branched portion, particularly via the nitrogen atom. As a result, the two payloads are connected to a single sub-Z.
[0117] In a particular embodiment, L 2 It has structure (2), [ka] In the formula, the wavy bond labeled * is connected to Z, and the wavy bond labeled ** is connected to the N-terminal NH of the polyglycine linker. LB 1 and LB 2 Each is a linker portion, and the two linker-payload portions connected to the branched nitrogen atom may be the same or different. In particular, each occurrence of D is the same. In certain embodiments, LB 2 Each occurrence of is the same. In certain embodiments, each occurrence of n is the same. In particular, L 3 The occurrences of and c are the same.
[0118] Connecting group Z Z is a connecting group. The term "connecting group" refers to a structural element that connects a part of a conjugate to another part of the same bioconjugate. In (1), Z connects antibody AB to the payload via a linker. The connecting group Z is a moiety that can be obtained by a metal-free click reaction, or by thiol ligation, or by transglutaminase-mediated transamidation. As those skilled in the art will appreciate, the exact nature of Z depends on the nature of F and Q. Preferred embodiments for Q and F are further defined below.
[0119] In a first embodiment, the connecting group Z can be obtained by a metal-free click reaction. As used herein, the connecting group Z may comprise a triazole moiety, an isoxazole moiety, a dihydroisoxazole moiety, a bicyclo[2.2.2]octa-5,7-diene-2,3-dione moiety, a bicyclo[2.2.2]octa-5-ene-2,3-dione moiety, a 7-thiabicyclo[2.2.1]hepta-2,5-diene-7,7-dioxide moiety, a 7-thiabicyclo[2.2.1]hepta-2-ene-7,7-dioxide moiety, a pyrazole moiety, a pyridine moiety, a dihydropyridine moiety, a pyridazine moiety, or a dihydropyridazine moiety
[0120] In certain embodiments, Q comprises a cyclic alkyne moiety, F is an azide, and Z comprises a triazole moiety formed by 1,3-dipolar cycloaddition of the alkyne moiety with the azide moiety.
[0121] In a second specific embodiment, the connecting group Z can be obtained by thiol ligation, and the connecting group Z is L 2 one connection to, and at least one connection to AB, optionally via L 1 A single connecting group Z may also have two connections to AB, and a crosslinking thiol-reactive probe Q is used. In one embodiment, L 1is absent (a=0), and Z is directly connected to AB. In certain embodiments, the linking group Z comprises a succinimidyl ring or a ring-opened succinic acid amide derivative thereof.
[0122] In a third specific embodiment, the linking group Z can be obtained by transglutaminase-mediated transamidation, and the linking group Z is L 2 to one connection, and at least one connection to AB, optionally via L 1 . In one embodiment, L 1 is absent (a=0), and Z is directly connected to AB.
[0123] Mode of conjugation The conjugate according to the present invention can be prepared by a mode of conjugation, wherein the conjugation reaction is thiol ligation or metal-free click reaction or transglutaminase, in particular microbial transglutaminase (MTGase) conjugation. When Z is absent, a is 0, and b is 0, the N-terminus of the polyglycine linker (Gly)n is directly conjugated to the antibody, for example via transglutaminase, in particular microbial transglutaminase (MTGase) conjugation.
[0124] Properties of modified antibody AB-((L 1 )a-F)x, in particular the properties of L 1 , a, and x depend on the mode of conjugation employed. x refers to the number of attachment points (conjugation sites) of (L1)a on the antibody, and is an integer in the range of 1 to 8. When Z (in the conjugate) or F (in the modified antibody) is directly attached to the antibody, L 1 is absent and a is 0. In this embodiment, the modified antibody may also be referred to as AB-(F)x.
[0125] x optionally represents the linker L 1This represents the amount of probe F present on the antibody via the linker L, and is an integer in the range of 1 to 8. In particular, x is an integer in the range of 1 to 6, more specifically x is 1, 2, 3, or 4, even more specifically x is 1 or 2, and most specifically x is 2. Typically, x refers to the average number of partial Z attached to the antibody. In certain embodiments, especially when conjugation is by a click reaction, the conjugate according to the present invention usually has the same amount of partial Z attached to the antibody, although the conjugation reaction may sometimes be slightly incomplete. In particular, each linker L 2 Linker L 2 It may contain two or more payloads, such as one or two payload molecules per unit.
[0126] In certain embodiments, a is 1, and the mode of conjugation involves conjugation via the antibody glycan, preferably via the N-glycosylation site. Typically, a modified antibody comprises one or more glycans having the structure -GlcNAc(Fuc)m-(G)e-Su-F, where e is an integer in the range of 0 to 20, Su is a monosaccharide, G is a monosaccharide moiety, GlcNAc is an N-acetylglucosamine moiety, Fuc is a fucose moiety, and m is 0 or 1. In other words, L1 is represented in particular by -GlcNAc(Fuc)m-(G)e-Su-, where GlcNAc(Fuc)m is attached to the peptide moiety of the antibody, Su is attached to Z or F, and GlcNAc is typically a core N-acetylglucosamine moiety present in the antibody glycan structure. The core N-acetylglucosamine moiety refers to the N-acetylglucosamine portion directly attached to the peptide chain of the antibody. This core N-acetylglucosamine moiety is optionally fucosylated (where m is 0 or 1), which is a common characteristic of antibodies.
[0127] (G)e represents the sugar type of the antibody. The present invention can be applied to antibodies of any sugar type. Typical monosaccharides present in glycans from which G can be selected include glucose, galactose, mannose, fucose, N-acetylglucosamine, N-acetylgalactosamine, N-acetylneuraminic acid, and xylose. Thus, (G)e can be a linear or branched oligosaccharide containing the e monosaccharide moiety. Typical glycans have e in the range of 4 to 16, preferably 6 to 10. In preferred embodiments, the antibody is trimmed so that e is 0. Such trimming can be carried out by an endoglycosidase enzyme such as EndoS. Conjugation via glycan preferably uses an N-glycosylation site, more preferably an N-glycosylation site connected to an asparagine amino acid of the antibody, and most preferably a conserved glycosylation site at amino acid N297 of the antibody.
[0128] Su is a monosaccharide containing F. Su is preferably selected from the group consisting of galactose (Gal), mannose (Man), glucose (Glc), N-acetylglucosamine (GlcNAc), N-acetylgalactosamine (GalNAc), N-acetylneuraminic acid or sialic acid (Sial), and fucose (Fuc). Su is preferably glucose or a galactose derivative, more preferably a galactose derivative, and most preferably N-acetylgalactosamine.
[0129] In an alternative embodiment, a is 0, and the conjugation site in the antibody is a cysteine residue, and in particular the cysteine residue is Optionally, after reduction of disulfide bonds known in the art, naturally occurring cysteine residues in the antibody are manipulated, preferably by amino acid substitution with cysteine, cysteine insertion, or introduction of a single cysteine residue or a peptide fragment containing a cysteine residue at the N-terminus or C-terminus.
[0130] In an alternative embodiment, a is 0, and the conjugation site in the antibody is a glutamine residue, which is either naturally present in the antibody or is manipulated by, preferably, amino acid substitution with glutamine, glutamine insertion, or introduction of a single glutamine residue or a peptide fragment containing a glutamine residue at the N-terminus or C-terminus.
[0131] In an alternative embodiment where Z is absent, a is 0, and b is 0, the N-terminus of the polyglycine linker (Gly)n is directly bound to the antibody. Therefore, in this embodiment, if Z is absent, L 1 and L 2 Therefore, if Z is not present, the N-terminus of the polyglycine linker (Gly)n binds directly to the antibody in the absence of any linker, for example, in the absence of any linker containing the saltase recognition sequence motif LPTXG (where X is any amino acid).
[0132] In one embodiment, Z is absent, a is 0, b is 0, and the N-terminus of the polyglycine linker (Gly)n is directly conjugated to an antibody via transglutaminase, particularly microbial transglutaminase (MTGase).
[0133] Transglutaminases (TGases), particularly microbial transglutaminases (MTGases), catalyze the transamidation reaction between specific surface-exposed glutamine (Gln) and lysine (Lys) residues on a protein substrate, cross-linking them via isopeptide bonds. Examples of TGases include naturally occurring transglutaminases, mutant transglutaminases, engineered transglutaminases, recombinant transglutaminases, microbial transglutaminases, mammalian transglutaminases, and protein-glutamine γ-glutamyltransferases (EC2.3.2.13), especially microbial transglutaminases (MTGases). The catalytic mechanism of MTGases involves nucleophilic attack of the target acyl donor, Gln, by the enzyme's active site cysteine to form a thioester intermediate. Subsequent nucleophilic attack of the thioester by an amine substrate acting as an acyl acceptor leads to the formation of the transamidation product. In particular, the conjugation site is Q295.
[0134] The most commonly used mTGase is a 38kDa enzyme derived from Streptomyces mobaraensis. Another transglutaminase found in bacteria is derived from Bacillus subtilisin (see US5,731,183). Various variants of mTGase have been developed, such as the mTGase disclosed in WO2017 / 059158 and WO2017 / 059160 (Merck), which have amino acid substitutions selected from the group consisting of (A)E300A, (B)I240A and P241A, (C)E249Q, and (D)E300A and Y302A.
[0135] AB represents antibody. Those skilled in the art will understand that the present invention can be applied to any antibody.
[0136] Process for the synthesis of antibody-drug conjugates In a second aspect, the present invention relates to a process for preparing an antibody-drug conjugate according to the present invention. The process according to the present invention comprises (i) reacting a modified antibody of structure AB-((L1)aF)x with (ii) a linker-drug construct of structure (5). The reaction is a conjugation reaction that forms a covalent bond between the payload and the antibody. The reaction is a metal-free click reaction or thiol ligation or transglutaminase, particularly microbial transglutaminase-mediated transamidation, forming an antibody-drug conjugate in which the drug is covalently bound to the antibody via a conjugate group Z formed by a metal-free click reaction between Q and F, or thiol ligation between Q and F, or transglutaminase, particularly microbial transglutaminase-mediated transamidation between Q and F. Alternatively, if a is 0, b is 0, and F is absent, the N-terminus of the polyglycine linker (Gly)n may be directly bound to the antibody, for example, via microbial transglutaminase (MTGase) conjugation. In the process according to the present invention, AB is an antibody, and L 1 A modified antibody of structure AB-((L1)aF)x, wherein a is a linker, a is 0 or 1, F is a click probe that can react with Q in a metal-free click reaction, or a thiol or its precursor that can react with Q in thiol ligation, or an acyl donor that can react with Q in microbial transglutaminase-mediated transamidation, and x is an integer in the range of 1 to 8. Reaction of Q and F of the linker-drug construct of structure (5) via a metal-free click reaction, thiol ligation, or transglutaminase-mediated transamidation forms a connecting group Z. In one embodiment, the modified antibody may be referred to as AB-(F)x. Methods for preparing modified antibodies are known in the art, for example, from WO2014 / 065661, WO2016 / 170186, and WO2016 / 053107, which are incorporated herein by reference. From the same document, the conjugation reaction between modified glycoproteins and linker-drug constructs containing cytotoxins and click probes is known to those skilled in the art.
[0137] In the process according to the present invention, the linker-drug construct has structure (5), [ka] During the ceremony, Q is a click probe capable of carrying out a metal-free click reaction, or a thiol-reactive probe, or an acyl-acceptor probe capable of reacting with acyl donor F in microbial transglutaminase-mediated transamidation. L 2 , L 3 D, n, b, and c are as defined above.
[0138] Metal-free click reaction Metal-free click reactions are well known in the art (see, for example, WO2014 / 065661 and Nguyen and Prescher, Nature rev.2020, doi:10.1038 / s41570-020-0205-0, both incorporated by reference), and can typically take the form of 1,3-dipolar cycloaddition or (4+2) cycloaddition. Alkyne-azidecyclo cycloaddition can be strain-enhanced (e.g., strain-enhanced alkyne-azide cycloaddition, SPAAC). In certain embodiments, the bioconjugation is a metal-free strain-enhanced cycloaddition, most specifically a metal-free strain-enhanced alkyne-azide cycloaddition. In certain embodiments, conjugation is achieved via cycloaddition, e.g., (4+2) cycloaddition or 1,3-dipolar cycloaddition, preferably 1,3-dipolar cycloaddition. A typical (4+2) cycloaddition is the Diels-Alder reaction, where Q is a diene or dienophile. As will be understood by those skilled in the art, the term “diene” in the context of the Diels-Alder reaction refers to a 1,3-(hetero)diene, including conjugated dienes (R2C=CR-CR=CR2), imines (e.g., R2C=CR-N=CR2 or R2C=CR-CR=NR, R2C=NN=CR2), and carbonyls (e.g., R2C=CR-CR=O or O=CR-CR=O). Hetero-Diels-Alder reactions with N and O-containing dienes are known in the art. Any diene known in the art to be suitable for (4+2) cycloaddition can be used as the reactive group Q. Specific dienes include tetrazine, 1,2-quinone, and triazine. Any dienophile known in the art to be suitable for (4+2) cycloaddition can be used as the reactive group Q, the dienophile being particularly the above-mentioned alkene or alkyne group, most specifically an alkyne group or a cyclic alkene. For the conjugation via (4+2) cycloaddition, Q may be a dienophile (where F is a diene), more specifically, Q may be an alkynyl group or a cycloalkenyl group, or may contain an alkynyl group or a cycloalkenyl group.Alternatively, for conjugation via (4+2) cycloaddition, Q may be a diene (and F is a dienophile), and more specifically, Q is a tetrazine group or comprises a tetrazine group.
[0139] For 1,3-dipolar cycloaddition, Q is a 1,3-dipole or a dipolarophile. Any 1,3-dipole known in the art to be suitable for 1,3-dipolar cycloaddition can be used as the reactive group Q. Specific 1,3-dipoles include azide groups, nitrone groups, nitrile oxide groups, nitrile imine groups, and diazo groups. Any dipolarophile known in the art to be suitable for 1,3-dipolar cycloaddition can be used as the reactive group Q, while the dipolarophile is in particular an alkene group or an alkyne group, most specifically an alkyne group. For conjugation via 1,3-dipolar cycloaddition, in particular Q is a dipolarophile (and F is a 1,3-dipole), and more specifically Q is an alkynyl group or comprises an alkynyl group.
[0140] Accordingly, in certain embodiments, Q is selected from dipolarophiles and dienophiles.
[0141] Click Probe Q Click probe Q is used in a conjugation reaction to connect the linker-drug construct to the antibody of structure AB-((L1)a-F)x. Q is reactive toward click probe F in a metal-free click reaction. Such click probes are known in the art and include cyclic alkenes, cyclic alkynes, azides, tetrazines, triazines, nitrones, nitrile oxides, nitrile imines, diazo compounds, ortho-quinones, dioxothiophenes, and sydnones. In particular, Q is a cyclic alkene or cyclic alkyne moiety, and most specifically Q is a cyclic alkyne moiety.
[0142] In certain embodiments, click probe Q includes a cyclic alkyne moiety. The alkynyl group may also be referred to as a (hetero)cycloalkynyl group, i.e., a heterocycloalkynyl group or a cycloalkynyl group, and the (hetero)cycloalkynyl group is optionally substituted. In particular, the (hetero)cycloalkynyl group is a (hetero)cycloheptynyl group, a (hetero)cyclooctinyl group, a (hetero)cyclononinyl group, or a (hetero)cyclodecynyl group. In this specification, the (hetero)cycloalkyne may be optionally substituted. In particular, the (hetero)cycloalkynyl group is optionally substituted with a (hetero)cycloheptynyl group or optionally substituted with a (hetero)cyclooctinyl group. Most specifically, the (hetero)cycloalkynyl group is a (hetero)cyclooctinyl group, and the (hetero)cyclooctinyl group is optionally substituted.
[0143] Certain cycloalkynyl groups include optionally substituted bicyclo[6.1.0]non-4-in-9-yl] group (BCN group) or optionally substituted 2-azatricyclo[10.4.0.04,9]hexadeca-1(16),4,6,8,12,14-hexaen-10-in-2-yl] (DBCO group).
[0144] Thiol ligation Thiol ligation for the preparation of antibody-drug conjugates is well known in the art and may also be referred to as alkylation of thiol groups. It typically takes the form of nucleophilic reactions such as nucleophilic substitution or Michael reactions. A particular Michael reaction is the maleimide-thiol reaction, which is widely used in bioconjugations. Therefore, in certain embodiments, Q is reactive in nucleophilic reactions, preferably nucleophilic substitution or Michael reactions. In this specification, Q preferably comprises a maleimide moiety, a haloacetamide moiety, an allenamide moiety, a phosphoamidite moiety, a cyanoethynyl moiety, a vinylsulfone, a vinylpyridine moiety, or a methylsulfonylphenyloxadiazole moiety, most preferably a maleimide moiety.
[0145] Thiol-reactive probe Q Thiol-reactive probe Q has a linker-drug construct structure AB-((L 1 ) a It is used in conjugation reactions to bind to an antibody of -F)x. Q is reactive to a thiol or its precursor F in thiol ligation. Such probes are known in the art and may be selected from the group consisting of maleimide moieties, haloacetamide moieties, allenamide moieties, phosphoamidite moieties, cyanoethynyl moieties, vinylsulfone, vinylpyridine moieties, or methylsulfonylphenyloxadiazole moieties. Most specifically, Q contains or is a maleimide moiety.
[0146] Transglutaminase (TGase)-mediated transamidation Transglutaminases (TGases), particularly microbial transglutaminases (MTGases), catalyze the transamidation reaction between specific surface-exposed glutamine (Gln) and lysine (Lys) residues on a protein substrate, cross-linking them via isopeptide bonds. The catalytic mechanism of MTGases involves nucleophilic attack of the target acyl donor, Gln, by the enzyme's active site cysteine to form a thioester intermediate. Subsequent nucleophilic attack of the thioester by an amine substrate acting as an acyl acceptor leads to the formation of the transamidation product. In particular, the conjugation site is Q295.
[0147] The most commonly used mTGase is a 38kDa enzyme derived from Streptomyces mobaraensis. Another transglutaminase found in bacteria is derived from Bacillus subtilisin (see US5,731,183). Various variants of mTGase have been developed, such as the mTGase disclosed in WO2017 / 059158 and WO2017 / 059160 (Merck), which have amino acid substitutions selected from the group consisting of (A)E300A, (B)I240A and P241A, (C)E249Q, and (D)E300A and Y302A.
[0148] Acyl Acceptor Probe Q Acyl-acid probe Q is a linker-drug construct with structure AB-((L 1 ) aQ is used in conjugation reactions to bind to antibodies of -F)x. Q is reactive to acyl donor F in transglutaminase, particularly in microbial transglutaminase-mediated transamidation. Such probes are known in the art, and the acyl acceptors commonly used in this reaction are primary amines. However, recent studies have shown that other acyl acceptors containing terminal -NH groups, namely alpha-effect nucleophiles such as hydrazines, hydrazides, and alkoxyamines, can be used (Chio et al., 2020. Angew Chem Int Ed Engl 59(33):13814-13820). Those skilled in the art will understand that the term "alpha effect" refers to the increased nucleophilicity of an atom due to the presence of an adjacent (alpha) atom with a lone pair of electrons, in this context referring to the increased nucleophilicity of the nitrogen atom of the terminal -NH of the acyl acceptor. In one embodiment, the acyl acceptor is selected from amines, e.g., primary amines; hydrazines; hydrazides; alkoxyamines or aryloxyamines. In further embodiments, the amine, hydrazine, hydrazide, or oxyamine is an aryl derivative, in particular an optionally substituted phenyl or optionally substituted benzyl derivative, e.g., optionally substituted phenylhydrazine. In one embodiment, the acyl acceptor is a hydrazine or hydrazide. In one embodiment, the acyl acceptor is a hydrazide or an optionally substituted arylhydrazine derivative. In further embodiments, the acyl acceptor is an optionally substituted arylhydrazine derivative or an optionally substituted arylhydrazide derivative. In yet another embodiment, the acyl acceptor is an optionally substituted phenylhydrazine or an optionally substituted phenylhydrazide derivative.
[0149] Reactive group F The reactive group F is a click probe, or a thiol or its precursor, or an acyl donor that can react with the acyl acceptor probe Q in microbial transglutaminase-mediated transamidation. Therefore, in the first embodiment, F is a click probe. Click probe F is used in a conjugation reaction to link a linker-drug construct to a modified antibody. F is reactive with click probe Q in a metal-free click reaction. Such click probes are known in the art and include cyclic alkenes, cyclic alkynes, azides, tetrazines, triazines, nitrones, nitrile oxides, nitrile imines, diazo compounds, ortho-quinones, dioxothiophenes, and cydonones.
[0150] In particular, F is reactive to cyclic alkenes and cyclic alkynes, and is typically selected from the group consisting of azides, tetrazines, triazines, nitrones, nitrile oxides, nitrile imines, diazo compounds, ortho-quinones, dioxothiophenes, and cydonones.
[0151] In particular, F is reactive to dienes such as tetrazine, 1,2-quinone, and triazine, and is typically selected from the group consisting of alkenes and alkynes, most specifically alkynes or cyclic alkenes.
[0152] In particular, click probe F is selected from azides, tetrazines, and cyclic alkenes. More specifically, click probe F is an azide.
[0153] In the second embodiment, F is a thiol or its precursor. The thiol or its precursor F is used in a conjugation reaction to link the linker-drug construct to a modified antibody. F is reactive to the thiol-reactive probe Q in thiol ligation. The thiol precursor in the context of bioconjugation comprises disulfides that are known in the art and may be naturally occurring disulfide crosslinks present in antibodies, or synthetically introduced disulfides, which are reduced as known in the art. In particular, F is a thiol group.
[0154] In the third embodiment, F is an acyl donor. The acyl donor is used in a conjugation reaction to link the linker-drug construct to the modified antibody. F is reactive to acyl acceptor probe Q in transglutaminase, particularly in microbial transglutaminase-mediated transamidation, and F is an acyl derivative, particularly an amide or carboxylic acid derivative, in particular the acyl group is in the side chain of an amino acid residue. In particular the amino acid is glutamine. In particular a is 0, and the amino acid, particularly glutamine, is in antibody AB.
[0155] Linker - Drug construct In a third aspect, the present invention relates to a linker-drug construct of structure (5), [ka] During the ceremony, Q is a click probe capable of performing a metal-free click reaction, or a thiol-reactive probe, or an acyl-acceptor probe capable of reacting with acyl donor F in transglutaminase-mediated transamidation. L 2 , L 3 The following relates to linker-drug constructs where D, n, b, and c are as defined above.
[0156] Linker-drug constructs and L provided in the context of the first and second aspects of the present invention 2 , L 3 The definitions and preferred embodiments of D, n, b, and c apply equally to the third aspect of the present invention. Linker-drug constructs according to this aspect are ideally suitable as intermediates in the preparation of antibody-drug conjugates according to the present invention. Thus, the present invention also relates to the structure AB-((L 1 This invention relates to the use of the linker-drug construct according to the present invention in metal-free click conjugation reactions, thiol ligation conjugation reactions, or transglutaminase-mediated transamidation conjugation reactions, particularly microbial transglutaminase-mediated transamidation conjugation reactions, with modified antibodies of )aF)x.
[0157] Purpose The present invention further relates to the use of the conjugate according to the present invention in medicine.
[0158] In a further embodiment, the present invention provides a method for treating a subject in need of treatment, comprising administering a conjugate according to the present invention to the subject.
[0159] In a further embodiment, the present invention provides a conjugate according to the present invention for use in therapeutic use, particularly for use in the treatment of subjects requiring therapeutic treatment.
[0160] In a further embodiment, the present invention provides the use of the conjugate according to the present invention in the manufacture of pharmaceuticals.
[0161] Administration is typically carried out using a therapeutically effective dose of the conjugate according to the present invention.
[0162] The present invention provides a method for treating a specific disease in a subject requiring treatment, further comprising the administration of a conjugate according to the present invention as defined above. In particular, the specific disease may be selected from cancer and autoimmune diseases, with the disease being cancer in particular. The subject requiring treatment is typically a cancer patient. The use of antibody-drug conjugates is well known in such treatments, particularly in the field of cancer treatment, and the conjugate according to the present invention is particularly suitable in this respect. In this embodiment of the method, the conjugate is typically administered in a therapeutically effective dose.
[0163] In a further embodiment, the present invention provides a conjugate for use in the treatment of specific diseases in subjects requiring treatment, particularly in the treatment of cancer.
[0164] In a further embodiment, the present invention provides the use of a conjugate according to the present invention for the preparation of a pharmaceutical or pharmaceutical composition for use in the treatment of a specific disease in a subject requiring treatment, preferably for use in the treatment of cancer.
[0165] In the context of this invention, administration refers to systemic administration. Therefore, in one embodiment, the method defined herein is for systemic administration of a conjugate. Considering the specificity of the conjugate, they can be administered systemically and, nevertheless, exert their activity within or near the target tissue (e.g., a tumor). Systemic administration has significant advantages over local administration because the drug can reach tumor metastases undetectable by imaging techniques, and it may also be applicable to hematological malignancies.
[0166] The present invention further provides a pharmaceutical composition comprising an antibody-payload conjugate according to the present invention and a pharmaceutically acceptable carrier.
[0167] Some aspects and embodiments of this disclosure are described below in more detail with reference to the following examples, which are illustrative only and not limiting.
[0168] Examples are shown in the following drawings. [Brief explanation of the drawing]
[0169] [Figure 1] This shows a plot of cLogP against the number of glycine or PEG units. [Examples]
[0170] Materials and methods Preparation of drug linkers Drug Linker DL-A [ka] [ka] Step 1: Alloc-Val-Ala-PABA(1) (29 g, 1 equivalent) was dissolved in MeCN (10V). K2CO3 (2 equivalents) was added. The reaction mixture was heated to 50°C. A solution of 4-nitrophenylcarbonochloride in MeCN (2 equivalents in 5V) was added. The reaction mixture was stirred at 50°C for 6 hours. Upon completion, the reaction mixture was filtered. The filtrate was concentrated under vacuum to obtain the crude residue. The latter was purified by flash column chromatography (silica) eluting with siRNA / DCM (0-20%) to obtain compound 2 (30 g, 72%).
[0171] Step 2: Exatecan mesylate (24 g, 1 equivalent) was dissolved in DMF (10V). DIPEA (3 equivalents) was added. Compound 2 (1.25 equivalents) was added, and the reaction mixture was stirred at 25°C for 16 hours.
[0172] Upon completion, water (30V) was added dropwise to the reaction mixture. The latter was stirred at 25°C for 30 minutes. The reaction mixture was filtered, the cake was washed with water (5V), collected, and completely dried to obtain compound 3 (29g, 77%).
[0173] Step 3: Compound 3 (30 g, 1 equivalent) was dissolved in DCM (10V). Pd(PPh3)4 (0.02 equivalents) and pyrrolidine (1.5 equivalents) were added. The reaction mixture was stirred at 25°C for 2 hours. Upon completion, the reaction mixture was concentrated under vacuum to obtain the crude residue. The latter was purified by flash column chromatography (silica) eluting with MeOH / DCM (0-8%) to obtain Compound 4 (17 g, 63%).
[0174] Step 4: To the solutions of compound 5 (5.32 g, 20 mmol) and compound 6 (3.8 g, 20 mmol) in acetonitrile / water (1 / 2, v / v, 100 mL), saturated NaHCO3 solution (40 mL) was added.
[0175] The reaction mixture was stirred at room temperature for 2 hours. Then, TFA (2.8 mL) was added, and stirring was continued for another 10 minutes. The mixture was directly purified by preparative RP-HPLC to obtain compound 7 as a white solid (6.1 g, 90%).
[0176] Step 5: A solution of compound 4 (3.08 g, 4.08 mmol) and compound 8 (1.44 g, 4.08 mmol) in anhydrous DMF (50 mL) is mixed with PyAOP (2.13 g, 4.08 mmol) and DIPEA.
[0177] (2.1 mL, 12.08 mmol) was added. The reaction mixture was stirred at room temperature for 10 minutes. Then, piperidine (2.0 mL) was added and stirring was continued for another 10 minutes.
[0178] The mixture was added to diethyl ether (500 mL) with stirring. The suspension was centrifuged, and the precipitate was collected by decantation. The precipitate was then dissolved in 40 mL of DMF and purified by preparative RP-HPLC to obtain compound 9 as a yellow solid TFA salt (2.4 g, 60%).
[0179] Step 6: To a solution of compound 9 (TFA salt, 814 mg, 0.83 mmol) and compound 7 (282 mg, 0.83 mmol) in anhydrous DMF (20 mL), AOP (367 mg, 0.83 mmol) and DIPEA (0.57 mL, 3.28 mmol) were added. The reaction mixture was stirred at room temperature for 10 minutes. The mixture was then purified by preparative RP-HPLC to obtain compound DL-A as a yellow solid (510 mg, 81%).
[0180] Preparative RP-HPLC method: Column: Phenomenex Gemini NX 5m, C18, 110Å, 150×50mm Equipment: Shimadzu LC using CTC IFC Mobile phase: A) Water (0.1% TFA), B) Acetonitrile Gradient: 10-65% B over 20 minutes, flow rate 50 mL / min Analytical HPLC: Column: Phenomenex Gemini NX 5m, C18, 110Å, 150×4.6mm Equipment: Shimadzu LC-2030 Mobile phase: A) Water (0.05% TFA), B) Acetonitrile (0.05% TFA) Gradient: 20-70% B over 15 minutes, flow rate 1.0 mL / min 220nm, 1191.6[M+H+] All desired HPLC fractions were pooled and freeze-dried using a Virtis Freezemobile 35EL.
[0181] Drug Linker DL-B Step 1: Synthesis of ((allyloxy)carbonyl)-glycyl-glycyl-glycine (22). [ka] Step 1 procedure: To a solution of compound 21 (8 g, 42.3 mmol, 1 equivalent) in THF / H2O (40 mL / 80 mL), Alloc-Cl (7.65 g, 63.5 mmol, 1.5 equivalents) and NaHCO3 (7.11 g, 84.6 mmol, 2 equivalents) were added under N2 protection at 30 ± 5 °C. The reaction mixture was stirred at 30 ± 5 °C for 2 hours. The reaction was monitored by LC-MS. The pH of the reaction solution was adjusted to 1-2. DCM (40 mL) was added to the reaction solution and stirred for 30 minutes. After filtration and washing with DCM (40 mL), the desired product of compound 22 was obtained as a solid (11 g, 69%).
[0182] 1 H NMR(400 MHz,DMSO-d6)δ ppm 12.61(s,1H),8.22(dt,J=12.3,5.8 Hz,2H),7.47(t,J=6.0 Hz,1H),5.91(ddt,J=17.2,10.6,5.3 Hz,1H),5.30(dq,J=17.3,1.8 Hz,1H),5.18(dq,J=10.5,1.5 Hz,1H),4.49(dt,J=5.3,1.6 Hz,2H),3.76(t,J=6.2 Hz,4H),3.67(d,J=6.1 Hz,2H). LCMS: (ES+)m / z = 274.2[M+H] + 94.49%, 1.25 minutes, at RT.
[0183] Step 2: Synthesis of methyl((allyloxy)carbonyl)-glycyl-glycyl-glycyl-glycyl-glycinate (23) [ka] Step 2 procedure: To a solution of compound 22 (10 g, 36.60 mmol, 1 equivalent) in DMF (100 mL), SM3 (6.66 g, 36.60 mmol, 1 equivalent), DIEA (23.65 g, 183 mmol, 5 equivalents), and T3P (13.97 g, 43.92 mmol, 1.2 equivalents) were added under N2 protection at 0 ± 5 °C. The reaction mixture was stirred at 30 ± 5 °C for 2 hours. The reaction was monitored by LC-MS. H2O (300 mL) was added and stirred for 30 minutes. After filtration and washing with H2O (50 mL), a moist cake was obtained. After drying at 40 °C, the desired product of compound 23 was obtained as an off-white solid (11.5 g, 69%).
[0184] 1 H NMR(400 MHz,DMSO-d6)δ 8.27(t,J=5.9 Hz,1H),8.16(d,J=9.4 Hz,3H),7.44(t,J=6.0 Hz,1H),5.91(ddt,J=16.1,10.6,5.3 Hz,1H),5.30(dq,J=17.1,1.8 Hz,1H),5.18(dd,J=10.4,1.8 Hz,1H),4.48(dt,J=5.3,1.6 Hz,2H),3.85(d,J=5.8 Hz,2H),3.75(dd,J=5.8,3.2 Hz,6H),3.65(d,J=15.1 Hz,5H). LCMS: (ES+)m / z = 402.10[M+H] + 93.13%, 0.42 minutes, at RT.
[0185] Step 3: Synthesis of ((allyloxy)carbonyl)-glycyl-glycyl-glycyl-glycyl-glycine (24) [ka] Step 3 procedure: Mixed compound 23 (3 g, 7.47 mmol, 1 equivalent) in MeOH / H2O (30 mL / 30 mL) was mixed with LiOH (0.214 g, 8.97 mmol, 1.2 equivalents) under N2 protection at 0 ± 5 °C. The reaction mixture was stirred at 0 ± 5 °C for 6 hours. The reaction was monitored by LC-MS. The pH of the reaction solution was adjusted to 1-2, DCM (5V) was added, and the mixture was stirred for 30 minutes. After filtration and washing with DCM (15 mL), a moist cake was obtained. After drying at 25 °C, the desired product of compound 24 was obtained as an off-white solid (1.9 g, 66%).
[0186] 1 H NMR(400 MHz,DMSO-d6)δ 8.16(dq,J=10.3,6.2 Hz,5H),7.44(t,J=6.1 Hz,1H),5.91(ddt,J=16.2,10.6,5.3 Hz,1H),5.30(dd,J=17.3,1.9 Hz,1H),5.22-5.14(m,1H),4.52-4.44(m,2H),3.78-3.72(m,10H). LCMS:(ES+)m / z=388[M+H] + 95.60%, 0.94 minutes, in RT.
[0187] Step 4: Synthesis of allyl((R)-1-(((R)-1-((4-(((((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolidino[1,2-b]quinoline-1-yl)carbamoyl)oxy)methyl)phenyl)amino)-1-oxopropan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)carbamate (26) [ka] Step 4 procedure: To a solution of exatecan mesylate (4.5 g, 7.47 mmol, 1 equivalent) and DIEA (2.41 g, 18.68 mmol, 2.5 equivalents) in DMF (45 mL), active ester 25 (5.07 g, 9.34 mmol, 1.25 equivalents) was added under N2 protection at 30 ± 5 °C. The reaction mixture was stirred at 30 ± 5 °C for 2 hours. The reaction was monitored by LC-MS. H2O (135 mL) was added and the mixture was stirred for 30 minutes. After filtration and washing the cake with H2O (135 mL), a moist cake was obtained. After drying at 25 °C, the desired product of compound 26 was obtained as a light brown solid (6 g, 69%).
[0188] LCMS: (ES+)m / z = 839.35[M+H] + 93.99%, 0.68 minutes, in RT.
[0189] Step 5: Synthesis of 4-((R)-2-((R)-2-amino-3-methylbutanamide)propanamide)benzyl((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolidino[1,2-b]quinoline-1-yl)carbamate (27) [ka] Step 5 procedure: A mixture of compound 26 (6 g, 7.15 mmol, 1 equivalent) and Pd(PPh3)4 (0.165 g, 0.143 mmol, 0.02 equivalents) in DCM (60 mL) was mixed with pyrrolidine (0.763 g, 10.73 mmol, 1.5 equivalents) under N2 protection at 30 ± 5 °C. The reaction mixture was stirred at 30 ± 5 °C for 2 hours. The reaction was monitored by LC-MS. After filtration and purification by cicagel column (DCM / MeOH), the desired product of compound 27 was obtained as a light brown solid (4 g, 74%).
[0190] 1H NMR(300 MHz,DMSO-d6)δ 10.08(s,1H),8.43(s,5H),8.04(d,J=8.8 Hz,1H),7.63(dd,J=15.3,9.6 Hz,3H),7.39(d,J=8.2 Hz,2H),7.28(s,1H),6.51(s,1H),5.44(s,2H),5.32-4.99(m,5H),4.46(d,J=14.1 Hz,1H),3.18(s,4H),3.08-2.98(m,2H),2.39(td,J=5.6,4.3,2.7 Hz,1H),1.32(d,J=7.0 Hz,3H),0.85(dd,J=29.6,6.9 Hz,9H). LCMS: (ES+)m / z = 755.35[M+H] + 99.81%, 0.525 minutes, at RT.
[0191] Step 6: Synthesis of allyl((16R,19R)-20-((4-(((((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolidino[1,2-b]quinoline-1-yl)carbamoyl)oxy)methyl)phenyl)amino)-16-isopropyl-19-methyl-2,5,8,11,14,17,20-heptaoxo-3,6,9,12,15,18-hexaazycosyl)carbamate (28) [ka] Step 6 procedure: To a solution of compound 27 (3.1 g, 4.107 mmol, 1 equivalent) in DMF (31 mL), T3P (1.96 g, 6.16 mmol, 1.5 equivalents), DIEA (0.796 g, 6.16 mmol, 1.5 equivalents), and compound 24 (2.07 g, 5.34 mmol, 1.3 equivalents) were added under N2 protection at 0 ± 5 °C. The reaction mixture was stirred at 30 ± 5 °C for 2 hours. The reaction was monitored by LC-MS. After filtration and purification by preparative HPLC (0.1% FA in H2O / ACN), the desired product of compound 28 was obtained as a pale yellow solid (0.34 g, 7%).
[0192] 1 H NMR(400 MHz,DMSO-d6)δ 9.94(s,1H),8.26(d,J=6.9 Hz,1H),8.20-8.04(m,4H),7.84(d,J=8.8 Hz,1H),7.77(d,J=10.9 Hz,1H),7.60(d,J=8.2 Hz,2H),7.44(t,J=6.1 Hz,1H),7.37(d,J=8.2 Hz,2H),7.31(s,1H),5.90(ddt,J=16.1,10.5,5.3 Hz,1H),5.45(s,2H),5.38-5.13(m,5H),5.08(s,2H),4.47(dt,J=5.3,1.7 Hz,2H),4.37(t,J=7.0 Hz,1H),4.22(dd,J=8.7,6.7 Hz,1H),3.82-3.69(m,8H),3.65(d,J=6.1 Hz,5H),2.37(d,J=1.9 Hz,3H),2.16(d,J=23.6 Hz,2H),2.03-1.80(m,4H),1.31(d,J=7.1 Hz,3H),1.00-0.73(m,9H). LCMS: (ES+)m / z = 1124.50[M+H] + 93.57%, 0.80 minutes, at RT.
[0193] Step 7: Synthesis of 4-((2R,5R)-20-amino-5-isopropyl-2-methyl-4,7,10,13,16,19-hexaoxo-3,6,9,12,15,18-hexaazycosamide)benzyl((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolidino[1,2-b]quinoline-1-yl)carbamate (29) [ka] Step 7 procedure: To a mixture of compound 28 (0.310 g, 0.2758 mmol, 1 equivalent) in DCM (31 mL), Pd(PPh3)4 (0.080 g, 0.06895 mmol, 0.25 equivalents) and PhSiH3 (0.447 g, 4.13 mmol, 15 equivalents) were added under N2 protection at 30 ± 5 °C. The microwave reaction mixture was stirred at 40 ± 5 °C for 0.5 hours. The reaction was monitored by LC-MS. After filtration and purification by preparative HPLC (0.05% TFA in H2O / ACN), the desired product of compound 29 was obtained as a pale yellow solid (0.185 g, 65%).
[0194] 1 H NMR(400 MHz,DMSO-d6)δ 9.94(s,1H),8.21-8.04(m,4H),7.87(t,J=7.4 Hz,2H),7.71(d,J=7.5 Hz,1H),7.59(dd,J=7.3,5.3 Hz,2H),7.40-7.28(m,5H),6.52(s,1H),5.45(s,2H),5.34-5.19(m,3H),5.08(s,2H),4.38(q,J=7.1 Hz,1H),4.22(t,J=7.6 Hz,2H),3.75(tt,J=12.2,5.2 Hz,8H),3.67(d,J=6.1 Hz,2H),3.22(s,2H),3.10(d,J=17.7 Hz,1H),2.54(s,1H),2.37(d,J=1.9 Hz,3H),2.14(d,J=7.4 Hz,1H),2.03-1.93(m,1H),1.87(dt,J=16.7,7.0 Hz,2H),1.30(d,J=7.1 Hz,3H),0.92-0.79(m,9H). LCMS: (ES+)m / z = 1040.45[M+H] + 96.14%, 0.72 minutes, at RT.
[0195] Step 8A: Synthesis of DBCO-activated ester [ka] Step 8A procedure: To a solution of DBCO acid (0.200 g, 0.655 mmol, 1 equivalent) in DCM (1 mL), NHS (0.090 g, 0.786 mmol, 1.2 equivalents) and DCC (0.162 g, 0.786 mmol, 1.2 equivalents) were added under N2 protection at 20±5°C. The reaction mixture was stirred at 20±5°C for 1 hour. The reaction was monitored by LC-MS. After concentration and purification by preparative HPLC (H2O / ACN), the desired product, DBCO active ester, was obtained as an off-white solid (110 mg, 42%).
[0196] LCMS: (ES+)m / z = 403.05[M+H] + 97.1%, 0.95 minutes, at RT.
[0197] Step 8: Synthesis of DL-B [ka] Step 8: To a mixture of compound 29 (0.037 g, 0.03557 mmol, 1 equivalent) in DMF (1 mL), DIEA (0.01 g, 0.07825 mmol, 2.2 equivalents) and DBCO active ester (0.0286 g, 0.07114 mmol, 2.0 equivalents) were added under N2 protection at 30 ± 5 °C. The reaction mixture was stirred at 30 ± 5 °C for 4 hours. The reaction was monitored by LC-MS. After filtration and purification by preparative HPLC (0.05% TFA in H2O / ACN), the desired DL-B product was obtained as a pale yellow solid (3.9 mg, 8%).
[0198] LCMS: (ES+)m / z = 1328.55[M+H] + 85.0%, 0.82 minutes, at RT.
[0199] Drug Linker DL-C Synthesis of Compound 31 Step 1: Synthesis of 2-(4-(hydroxymethyl)-2-nitrophenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyltriacetate (31-1) [ka] Step 1 procedure: To a solution of SM1 (20 g, 118.2 mmol, 1 equivalent) and SM2 (56.4 g, 141.9 mmol, 1.2 equivalents) in ACN (200 mL), Ag2O (41.1 g, 177.4 mmol, 1.5 equivalents) was added under N2 protection at 15 ± 5 °C. The reaction mixture was stirred at 15 ± 5 °C for 4 hours. The reaction was monitored by LC-MS. After filtration and purification by silica gel (acidic) column (siRNA / PE), the desired product 31-1 was obtained as an off-white solid (35 g, 61%).
[0200] 1H NMR(300 MHz,DMSO-d6)δ ppm 7.80(d,J=2.1 Hz,1H),7.62(dd,J=8.7,2.1 Hz,1H),7.39(d,J=8.6 Hz,1H),5.72(d,J=7.8 Hz,1H),5.52-5.39(m,2H),5.17-5.06(m,2H),4.75(d,J=9.9 Hz,1H),4.52(d,J=5.6 Hz,2H),3.66(s,3H),2.01(d,J=6.4 Hz,9H). LCMS: (ES+)m / z = 508[M+Na] + 90.86%, 1.89 minutes, at RT.
[0201] Step 2: Synthesis of 2-(4-(((tert-butyldimethylsilyl)oxy)methyl)-2-nitrophenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyltriacetate (31-2) [ka] Step 2 procedure: To a solution of 31-1 (35.0 g, 72.1 mmol, 1 equivalent) in DCM (350 mL), imidazole (7.4 g, 108.2 mmol, 1.5 equivalents) and TBSCl (12.0 g, 79.3 mmol, 1.1 equivalents) were added under N2 protection at 20 ± 5 °C. The reaction mixture was stirred at 20 ± 5 °C for 2 hours. The reaction was monitored by LC-MS. After washing with pure water (350 mL x 2) and drying over anhydrous NaSO4, the organic phase was concentrated to dryness. The desired product 31-2 was obtained as an off-white solid (32 g, 74%).
[0202] 1 H NMR(400 MHz,DMSO-d6)δ ppm 8.37(s,7H),7.70(d,J=2.1 Hz,1H),7.53(dd,J=8.7,2.2 Hz,2H),7.35(d,J=8.7 Hz,1H),5.67(d,J=7.8 Hz,1H),5.38(t,J=9.5 Hz,1H),5.08-4.96(m,2H),4.76-4.53(m,3H),3.56(s,3H),2.10-1.78(m,9H),0.81(s,8H),0.08--0.22(m,6H). LCMS: (ES+)m / z = 622.20[M+Na] + 93.26%, 3.18 minutes, in RT.
[0203] Step 3: Synthesis of 2-(2-amino-4-(((tert-butyldimethylsilyl)oxy)methyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyltriacetate (31-3) [ka] Step 3 procedure: A mixture of 31-2 (32 g, 53.4 mmol, 1 equivalent) and Zn (4.0 g, 58.7 mmol, 1.1 equivalents) in MeOH / H2O (320 mL / 32 mL) was mixed with acetic acid (16 mL, 0.5 vol) under N2 protection at 15 ± 5 °C. The reaction mixture was stirred at 15 ± 5 °C for 2 hours. The reaction was monitored by LC-MS. After filtration, extraction with ethyl acetate, and purification by silica gel (acidic) column (ethyl acetate / PE), the desired product 31-3 was obtained as an off-white solid (13 g, 43%).
[0204] 1H NMR(300 MHz,DMSO-d6)δ ppm 6.83(d,J=8.2 Hz,1H),6.65(d,J=2.0 Hz,1H),6.46(dd,J=8.2,2.0 Hz,1H),5.55-5.39(m,2H),5.15-5.02(m,2H),4.71-4.60(m,3H),4.53(s,2H),3.66(s,3H),2.07-1.99(m,9H),0.90(s,9H),0.07(s,6H). LCMS: (ES+)m / z = 570.4[M+H] + 95.41%, 2.75 minutes, at RT.
[0205] Step 4: Synthesis of 2-(2-(((allyloxy)carbonyl)amino)-4-(((tert-butyldimethylsilyl)oxy)methyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyltriacetate (31-4) [ka] Step 4 procedure: AllocCl (2.8 g, 22.8 mmol, 1.0 equivalent) was added to a mixture of 31-3 (13 g, 22.8 mmol, 1 equivalent) and NaHCO3 (2.9 g, 34.2 mmol, 1.5 equivalent) in THF (90 mL) under N2 protection at 15 ± 5 °C. The reaction mixture was stirred at 15 ± 5 °C for 2 hours. The reaction was monitored by LC-MS. After filtration and extraction with SiO2 (130 mL), the desired product 31-4 was obtained as an off-white solid (11.5 g, 77%).
[0206] 1H NMR(300 MHz,DMSO-d6)δ ppm 8.12(s,1H),7.69(s,1H),7.12-6.99(m,2H),5.96(ddd,J=17.2,10.5,5.3 Hz,1H),5.58-5.33(m,3H),5.26-5.03(m,3H),4.73-4.56(m,5H),3.65(s,3H),2.07-1.98(m,9H),0.91(s,9H),0.08(s,6H). LCMS: (ES+)m / z = 676.4[M+Na] + 91.34%, 3.22 minutes, at RT.
[0207] Step 5: Synthesis of 2-(2-(((allyloxy)carbonyl)amino)-4-(hydroxymethyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyltriacetate (31-5) [ka] Step 5 procedure: To a solution of 31-4 (11.5 g, 17.6 mmol, 1 equivalent) and TEA.3HF (5.8 g, 35.2 mmol, 2.0 equivalents) in THF (115 mL), TEA (10.7 g, 105.5 mmol, 6.0 equivalents) was added under N2 protection at 15 ± 5 °C. The reaction mixture was stirred at 15 ± 5 °C for 48 hours. The reaction was monitored by LC-MS. After packing with H2O (57.5 mL) and extraction with SiO (57.5 mL x 2), the organic phase was concentrated to dryness. The desired product 31-5 was obtained as an off-white solid (6.8 g, 72%).
[0208] 1H NMR(300 MHz,DMSO-d6)δ ppm 8.14(s,1H),7.67(s,1H),7.10-6.99(m,2H),5.97(ddt,J=17.3,10.6,5.3 Hz,1H),5.57-5.50(m,1H),5.46(d,J=9.6 Hz,1H),5.38(dq,J=17.2,1.7 Hz,1H),5.25(q,J=1.5 Hz,1H),5.23-5.15(m,2H),5.09(t,J=9.7 Hz,1H),4.70(d,J=9.9 Hz,1H),4.59(dt,J=5.3,1.6 Hz,2H),4.42(d,J=5.6 Hz,2H),3.65(s,3H),2.07-1.95(m,9H). LCMS: (ES+)m / z = 562.2[M+Na] + 90.50%, 2.08 minutes, in RT.
[0209] Step 6: Synthesis of 2-(2-(((allyloxy)carbonyl)amino)-4-((((4-nitrophenoxy)carbonyl)oxy)methyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyltriacetate (31) [ka] Step 6 procedure: To a solution of 31-5 (6.8 g, 12.6 mmol, 1 equivalent) and SM3 (4.6 g, 15.1 mmol, 1.2 equivalents) in DMF (68 mL), DIEA (2.4 g, 18.9 mmol, 1.5 equivalents) was added under N2 protection at 15 ± 5 °C. The reaction mixture was stirred at 15 ± 5 °C for 4 hours. The reaction was monitored by LC-MS. After packing with H2O (68 mL) and extraction with Depositphotos (68 mL x 8), the organic phase was washed with water (68 mL x 4) to remove residual DMF. After purification by silica gel (acidic) column ( Depositphotos / PE), the desired product 31 was obtained as an off-white solid (3.3 g, 37%).
[0210] 1H NMR(300 MHz,DMSO-d6)δ ppm 8.37-8.26(m,3H),7.83(s,1H),7.63-7.54(m,2H),7.23(dd,J=8.4,2.0 Hz,1H),7.16(d,J=8.5 Hz,1H),6.06-5.90(m,1H),5.63(d,J=7.7 Hz,1H),5.49(t,J=9.6 Hz,1H),5.39(dq,J=17.2,1.7 Hz,1H),5.28-5.12(m,4H),4.73(d,J=9.9 Hz,1H),4.61(dt,J=5.4,1.5 Hz,2H),3.65(d,J=1.3 Hz, 3H), 2.08-1.97 (m, 9H). LCMS: (ES+)m / z = 727.6[M+Na] + 94.37%, 2.76 minutes, at RT.
[0211] Step 1: Synthesis of (2S,3R,4S,5S,6S)-2-(2-(((allyloxy)carbonyl)amino)-4-(((((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolidino[1,2-b]quinoline-1-yl)carbamoyl)oxy)methyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyltriacetate (32) [ka] Step 1 procedure: To a solution of compound 31 (8 g, 11.4 mmol, 1 equivalent) in DMF (160 mL), DIEA (2.9 g, 22.7 mmol, 2.0 equivalent) and exatecan mesylate (6.0 g, 11.4 mmol, 1.0 equivalent) were added under N2 protection at 20 ± 5 °C. The reaction mixture was stirred at 20 ± 5 °C for 16 hours. The reaction was monitored by LC-MS. After packing with H2O (160 mL) and extraction with SiO (160 mL), the organic phase was washed with water (80 mL). The organic phase was dried over Na2SO4, concentrated to dryness, and then slurryed with MTBE (40 mL) to obtain the desired product 32 as an off-white solid (9 g, 79%).
[0212] LCMS: (ES+)m / z = 1001.30[M+H] + 82.53%, 4.06 minutes, in RT.
[0213] Step 2: Synthesis of (2S,3R,4S,5S,6S)-2-(2-amino-4-(((((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolidino[1,2-b]quinoline-1-yl)carbamoyl)oxy)methyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyltriacetate (33) [ka] Step 2 procedure: To a mixture of compound 32 (9 g, 9.0 mmol, 1 equivalent) in DMF (180 mL), pyrrolidine (0.96 g, 13.5 mmol, 1.5 equivalents) and Pd(PPh3)4 (0.21 g, 0.18 mmol, 0.02 equivalents) were added under N2 protection at 20 ± 5 °C. The reaction mixture was stirred at 20 ± 5 °C for 12 hours. The reaction was monitored by LC-MS. The reaction product was quenched with H2O (90 mL). The organic phase was dried over Na2SO4 and concentrated to dryness. After purification by preparative HPLC (0.05% TFA, ACN) and lyophilization, the desired product 33 was obtained as a white solid (3.1 g, 37%).
[0214] LCMS:(ES+)m / z=917.2[M+H] + 94.00%, 3.67 minutes, in RT.
[0215] Step 3: Synthesis of (2S,3R,4S,5S,6S)-2-(2-(1-(9H-fluoren-9-yl)-3,6,9,12,15-pentaoxo-2-oxa-4,7,10,13,16-pentazaoctadecane-18-amide)-4-(((((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolidino[1,2-b]quinoline-1-yl)carbamoyl)oxy)methyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyltriacetate (35) [ka] Step 3 procedure: To a mixture of compound 34 (see step 3A, 1.26 g, 2.4 mmol, 1.1 equivalents) in DMF (40 mL), DIEA (0.34 g, 2.6 mmol, 1.2 equivalents) and HATU (1.00 g, 2.6 mmol, 1.2 equivalents) were added under N2 protection at 20 ± 5 °C. The reaction mixture was stirred at 20 ± 5 °C for 0.5 hours. Compound 33 (2.0 g, 2.2 mmol, 1.0 equivalent) was added to the mixture. The reaction mixture was stirred at 20 ± 5 °C for 16 hours. The reaction was monitored by LC-MS. DMSO (60 mL) was added to the reaction mixture. After purification by preparative HPLC (0.05% TFA, MeOH) and lyophilization, the desired product 35 was obtained as a white solid (1.3 g, 41%).
[0216] LCMS:(ES+)m / z=712.8[1 / 2M+H] + 95.69%, 3.79 minutes, in RT.
[0217] Process 3A: [ka] [Table 1] Step 4: Synthesis of (2S,3R,4S,5S,6S)-2-(2-(14-amino-4,7,10,13-tetraoxo-3,6,9,12-tetraazatetradecanamide)-4-(((((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolidino[1,2-b]quinoline-1-yl)carbamoyl)oxy)methyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyltriacetate (36) [ka] Step 4 procedure: A mixture of compound 35 (300 mg, 0.21 mmol, 1.0 equivalent) in DMF (40 mL) is mixed with piperidine. (12.6 mg, 0.15 mmol, 0.7 equivalents) was added under N2 protection at 20±5°C. The reaction mixture was stirred at 20±5°C for 3 hours. The reaction was monitored by LC-MS. DMSO (6 mL) was added to the reaction mixture. After purification by preparative HPLC (0.05% TFA, MeOH) and lyophilization, the desired product 36 was obtained as a white solid (100 mg, 39%).
[0218] LCMS:(ES+)m / z=1202.4[M+H] + 89.83%, 3.17 minutes, in RT.
[0219] Step 5: Synthesis of ((2S,3S,4S,5R,6S)-6-(2-(14-amino-4,7,10,13-tetraoxo-3,6,9,12-tetraazatetradecanamide)-4-(((((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolidino[1,2-b]quinoline-1-yl)carbamoyl)oxy)methyl)phenoxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid (37) [ka] Step 5 procedure: Compound 36 (100 mg, 0.083 mmol, 1.0 equivalent) was added to a mixture of compound 36 in MeOH / H2O (1 mL / 1 mL) with K2CO3 (57.49 mg, 0.416 mmol, 5.0 equivalents) under N2 protection at 20 ± 5 °C. The reaction mixture was stirred at 20 ± 5 °C for 16 hours. The reaction was monitored by LC-MS. The pH of the reaction mixture was adjusted to 4-6 with 2 M HCl. After lyophilization, the desired product 37 was obtained as a white solid (80 mg, 91%).
[0220] LCMS: (ES+)m / z = 1424.46[M+H]+ 70.69%, 2.75 minutes, at RT.
[0221] Step 6: Synthesis of (2S,3S,4S,5R,6S)-6-(2-(18-(2,5-dioxo-2,5-dihydro-1H-pyrrole-1-yl)-4,7,10,13,16-pentaoxo-3,6,9,12,15-pentazaoctadecanamide)-4-(((((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolidino[1,2-b]quinoline-1-yl)carbamoyl)oxy)methyl)phenoxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid (DL-C) [ka] Step 6 procedure: To a mixture of compound 37 (125 mg, 0.118 mmol, 1.0 equivalent) in DMF (2.5 mL), DIEA (15.21 mg, 0.118 mmol, 1.0 equivalent) and compound 38 (31.33 mg, 0.118 mmol, 1.0 equivalent) were added under N2 protection at 20±5°C. The reaction mixture was stirred at 20±5°C for 2 hours. The reaction was monitored by LC-MS. The pH of the reaction mixture was adjusted to 5-6 with 0.5 M HCl. After purification by preparative HPLC (0.05% TFA, MeOH) and lyophilization, the desired product DL-C was obtained as a pale yellow solid (20 mg, 14%).
[0222] LCMS:(ES+)m / z=1213.4[M+H] + 91.82%, 2.82 minutes, at RT.
[0223] Drug Linker DL-D Synthesis of compound 41 Synthesis of (3-(2,5-dioxo-2,5-dihydro-1H-pyrrole-1-yl)propanoyl)glycylglycylglycylglycylglycyl-L-valyl-L-alanine (41) [ka] Step 1-1 procedure: DMF (300 mL) and CTC resin (20.0 g, 1.6 mmol / g, 32.0 mmol, 1.0 equivalent) were added to SPPS reactor A at 25±5°C. The mixture was bubbling with nitrogen and allowed to swell for 1 hour. SM1-1 (39.4 g, 96.0 mmol, 3.0 equivalent) and DIEA (20.7 g, 160.0 mmol, 5.0 equivalent) were added to the mixture. The mixture was bubbling with nitrogen for 1.5 hours. The reaction was monitored by LCMS. The mixture was filtered and washed with DMF (200 mL x 3).
[0224] Steps 1-2: Piperidine / DMF solution (200 mL, 20 v / v%) was added to SPPS reactor A at room temperature. The reaction mixture was bubbling with nitrogen for 40 minutes. The reaction was monitored by LC-MS (following the sampling procedure described above). The mixture was washed with DMF (200 mL) until the pH was approximately 7. SM1-2 (19.7 g, 48.0 mmol, 1.5 equivalents), HOBT (6.5 g, 48.0 mmol, 1.5 equivalents), DIEA (6.2 g, 48.0 mmol, 1.5 equivalents), and DMF (300 mL) were added to SPPS reactor B. The reaction system was cooled to 0°C, and HATU (18.3 g, 48.0 mmol, 1.5 equivalents) was added. The reaction mixture was stirred for 10 minutes and then transferred to SPPS reactor A. The reaction mixture was bubbling with nitrogen for 1.5 hours. The reaction was monitored by LC-MS. (Following the sampling procedure described above), the mixture was filtered and washed with DMF (200 mL x 3).
[0225] Steps 1-3: Piperidine / DMF solution (200 mL, 20 v / v%) was added to SPPS reactor A at room temperature. The reaction mixture was bubbling with nitrogen for 40 minutes. The reaction was monitored by LC-MS (following the sampling procedure described above). The mixture was washed with DMF (200 mL) until the pH was approximately 7. SM1-3 (17.0 g, 48.0 mmol, 1.5 equivalents), HOBT (6.5 g, 48.0 mmol, 1.5 equivalents), DIEA (6.2 g, 48.0 mmol, 1.5 equivalents), and DMF (300 mL) were added to SPPS reactor B. The reaction system was cooled to 0°C, and HATU (18.3 g, 48.0 mmol, 1.5 equivalents) was added. The reaction mixture was stirred for 10 minutes and then transferred to SPPS reactor A. The reaction mixture was bubbling with nitrogen for 1.5 hours. The reaction was monitored by LC-MS. (Following the sampling procedure described above), the mixture was filtered and washed with DMF (200 mL x 3).
[0226] Steps 1-4: Piperidine / DMF solution (200 mL, 20 v / v%) was added to SPPS reactor A at room temperature. The reaction mixture was bubbling with nitrogen for 40 minutes. The reaction was monitored by LC-MS (following the sampling procedure described above). The mixture was washed with DMF (200 mL) until the pH was approximately 7. SM1-4 (8.1 g, 48.0 mmol, 1.5 equivalents), HOBT (6.5 g, 48.0 mmol, 1.5 equivalents), DIEA (6.2 g, 48.0 mmol, 1.5 equivalents), and DMF (300 mL) were added to SPPS reactor B. The reaction system was cooled to 0°C, and HATU (18.3 g, 48.0 mmol, 1.5 equivalents) was added. The reaction mixture was stirred for 10 minutes and then transferred to SPPS reactor A. The reaction mixture was bubbling with nitrogen for 1.5 hours. The reaction was monitored by LC-MS. (Following the sampling procedure described above), the mixture was filtered and washed with DMF (200 mL x 3).
[0227] Steps 1-5: The moist cake was washed with DCM (200 mL x 4). TFE / DCM solution (300 mL, 20 v / v%) was added to SPPS reactor A. The mixture was bubbling with nitrogen and cut for 2 hours. After filtration and concentration, it was slurryed with MTBE (600 mL). The desired product 41 was obtained as a yellow solid (7 g, 37%).
[0228] LCMS: (ES+)m / z = 625.25[M+H] + 93.11%, 0.43 minutes, at RT.
[0229] Synthesis of (S)-2-(18-(2,5-dioxo-2,5-dihydro-1H-pyrrole-1-yl)-4,7,10,13,16-pentaoxo-3,6,9,12,15-pentazaoctadecanamide)-N-((S)-1-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolidino[1,2-b]quinoline-1-yl)amino)-1-oxopropan-2-yl)-3-methylbutanamide (DL-D) [ka] Step 2 procedure: To a mixture of compound 41 (50 mg, 0.08 mmol, 1.0 equivalent) in DMF (1 mL), HATU (30 mg, 0.10 mmol, 1.2 equivalents), DIEA (31 mg, 0.24 mmol, 3.0 equivalents), and EM (43 mg, 0.08 mmol, 1.0 equivalent) were added to the reactor at 20 ± 5 °C. The reaction mixture was stirred at 20 ± 5 °C for 4 hours. The reaction was monitored by LC-MS. The mixture was isolated and purified by preparative HPLC (water, 0.05% TFA in ACN). After lyophilization, the desired product DL-D was obtained as a yellow solid (18 mg, 22%).
[0230] 1H NMR(300 MHz,DMSO-d6)δ 8.44(d,J=8.6 Hz,1H),8.26(t,J=5.8 Hz,1H),8.11(ddt,J=20.3,11.5,6.4 Hz,6H),7.80(dd,J=9.9,6.8 Hz,2H),7.30(s,1H),5.54(dd,J=9.1,4.5 Hz,1H),5.42(s,2H),5.22-5.06(m,2H),4.26(q,J=6.9 Hz,1H),4.17(dd,J=8.7,6.7 Hz,1H),3.73(t,J=5.9 Hz,9H),3.60(d,J=1.8 Hz,2H),3.17(s,2H),2.42-2.37(m,4H),2.13(s,2H),1.89(dt,J=19.1,6.6 Hz,3H),1.30-1.23(m,5H),0.88-0.77(m,9H). LCMS: (ES+)m / z = 1042.40[M+H] + 98.00%, 1.09 minutes, in RT.
[0231] Synthetic Linker LN-B [ka] LN-B ADC synthesis ADC-A: Conjugation of DL-A The test ADC essentially contains exatecan as a warhead with a maleimide-Gly5 (or Gly3)-Val-Ala-PABA linker (DL-A) conjugated to the test monoclonal antibody via a hinge region cysteine residue, as described in Zammarchi et al., 2016. Mol Cancer Ther 15:2709. Briefly, the antibody was buffer-exchanged to histidine buffer at pH 6 using tangential flow filtration, the pH was adjusted to 7.5 using TRIS / EDTA pH 8.5 buffer, and the solution was reduced with tris(2-carboxyethyl)phosphine reducing agent (TCEP). Dimethylacetamide and the drug linker (3-fold excess relative to the antibody) were added to the solution. The conjugation reaction was incubated, then quenched with 3-fold molar excess N-acetylcysteine, and incubated again. Next, the pH was reduced to 6.0 using a histidine hydrochloride solution, and the resulting ADC was purified by tangential flow filtration, filtered, and stored at -70°C. The final yield was estimated by UV-Vis spectrophotometric analysis based on the starting antibody. The synthesis of drug linker DL-A is described above.
[0232] ADC-B:MTGase mediates the conjugation of LN-B to mAbA, followed by the conjugation of the subsequent drug linker DL-B. MAbA (91.6 mg, 2.58 mL) was diluted with PBS, pH 7.2 (91.6 mL). To the diluted antibody, 5.3 mg / mL EndoS solution (69.1 μL, 0.4 w / w%), 6.7 mg / mL MTGase solution (2.03 mL, 6 U / mg), and 10 mM LN-B (5.37 mg, 1.27 mL, 20 equivalents) were added. The resulting reaction mixture was mixed and incubated overnight at 37°C. The crude conjugate was purified by protein A chromatography (MabSelect SuRu). The purified mAbA-LN-B was determined by UV-A280 (4.12 mg / mL). To mAbA-LN-B (0.25 mg, 61.0 μL), PBS (114.0 μL) and propylene glycol (50.0 μL) were added, followed by 10 mM DL-B (22.8 μg, 0.86 μL, 10 equivalents) and DMA (25.0 μL). The conjugation reaction mixture was mixed and incubated overnight at 22°C. The final conjugation reaction mixture was analyzed by SEC (98.9% monomer), HIC (DAR 1.9), and RP (DAR 1.8).
[0233] ADC-C: DL-C Conjugation to mAbB mAbB (15 mg, 3.0 mL) was mixed with 500 mM Tris, pH 8 (25 mM EDTA) (150 μL). The resulting solution was mixed, and then 50 mM TCEP (14.5 μL, 7.0 equivalents) was added. The reduction reaction product was mixed, and then incubated at 22°C for 1.5 hours. To the reducing antibody solution (15 mg, 3.16 mL), 10 mM DL-C in DMSO (1.01 mg, 83.0 μL, 8.5 equivalents) and DMSO (268.6 μL) were added. The resulting conjugation reaction product was mixed, and then incubated at 22°C for 1 hour. After 1 hour of conjugation, an additional 10 mM DL-C (0.25 mg, 20.8 μL, 2.0 equivalents) was added, the reaction product was mixed, and the reaction was continued for another hour. The final conjugation reaction product was analyzed by SEC (94.2% monomer) and HIC (DAR6.0).
[0234] ADC-D: DL-D conjugation to mAbC mAbC (30 mg, 5.0 mL) was mixed with 500 mM Tris, pH 8 (25 mM EDTA) (250 μL). The resulting solution was mixed, and then 50 mM TCEP (26.7 μL, 6.5 equivalents) was added. The reduction reaction product was mixed, and then incubated at 22°C for 1.5 hours. To the reducing antibody solution (30 mg, 5.28 mL), 10 mM DL-D in DMSO (1.93 mg, 185 μL, 9.0 equivalents) and DMSO (401 μL) were added. The resulting conjugation reaction product was mixed, and then incubated at 22°C for 1 hour. The conjugation reaction product was analyzed by SEC (98.8% monomer), HIC (DAR 6.0), and RP (DAR 6.0).
[0235] *mAbA, mAbB, and mAbC each target different antigens. mAbA is the wild-type antibody. mAbB and mAbC contain the C228V mutation and contain only one heavy-to-heavy-chain disulfide bond.
[0236] agglomeration research A 2 mg test monoclonal antibody at 8.87 mg / mL was pH-adjusted with 5% 0.5 M Tris, 0.025 M EDTA, pH 8.5, reduced with 2.3 molar equivalents of TCEP, and then conjugated with 6 molar equivalents of drug linker. After buffer exchange with 30 mM histidine, 175 mM sucrose, pH 6.0 / PBS, the drug-to-antibody ratio (DAR) was determined by HIC / LC-MS, and monomer percentages were determined by size exclusion chromatography (SEC). A monomer percentage of 95% or higher was evaluated as low aggregation.
[0237] Example 1 - Aggregation study using exatecan linker Previous studies conducted by the inventors using PEG-based linkers and exatecan warheads showed unfavorable aggregation characteristics. Therefore, the inventors sought to identify alternative linker designs. A new linker was designed using multiple glycine residues instead of PEG, resulting in improved aggregation levels (data not shown). This glycine linker concept was then tested with a new construct based on a maleimide conjugation group and a Val-Ala-PABC cleavable moiety bound to exatecan.
[0238] The maleimide-Gly3-Val-Ala-PABC-exatecan construct was tested against the maleimide-Gly5-Val-Ala-PABC-exatecan construct (DL-A (its synthesis is described above), the Gly3 variant differs only in the number of Gly residues). LogP values (a measure of hydrophobicity) were estimated using CDD Vault software (Collaborative Drug Discovery Inc.) based on the method described in Gedeck et al., 2017, J. Chem. Inf. Model. 57, 8, 1847-1858. Model training information using publicly available datasets is available from CDD. The results are shown in Table 1.
[0239] Furthermore, correlation studies were conducted using reverse-phase HPLC (RP-HPLC). Two constructs were injected into RP-HPLC, and the retention time (Rt) correlated with hydrophobicity; that is, high Rt was associated with the hydrophobic construct, while low Rt was associated with the hydrophilic construct. The results are shown in Table 1.
[0240] The level of aggregation was evaluated during conjugation to the test antibody.
[0241] During conjugation, the inventors ideally aim for a monomer content or monomer percentage of 95% or more. Lower monomer value percentages are generally interpreted as a higher degree of aggregation. Therefore, it can be agreed that a monomer value percentage of 95% or more means a very low level of aggregation or no aggregation at all, while values below this threshold are often interpreted as a higher level of aggregation.
[0242] result [Table 2] Consideration These results clearly demonstrate the enhanced hydrophilicity properties of the novel pentaglysin spacer / linker in drug linker constructs. The incorporation of the Gly5 motif allowed the constructs to exhibit increased hydrophilicity and lower aggregation levels for optimal conjugation processes. The Gly5-based constructs showed no aggregation, compared to the moderate aggregation observed in the Gly3-based versions.
[0243] Example 2 - Comparison of cLogP values of different polyglycines and PEG linkers. The cLogP values were calculated as described above for 5-8 length polyglycine and polyethylene glycol (PEG) linkers having two different conjugation groups, maleimide (Mal) and dibenzocyclooctin (DBCO). PEG is commonly used in linkers to enhance hydrophilicity. The values are shown in Table 2 below. [Table 3]
[0244] These results are plotted in Figure 1. It is easy to see that for the same number of units, glycine results in a lower cLogP. Furthermore, glycine has a stronger effect on lowering cLogP per added unit.
[0245] Example 3 - Conjugation study using exatecan linker and PEG vs. glycine Both Mal-Gly5-VA-PABC-exatecan (DL-A) and variants having PEG5 instead of Gly5 were conjugated to the same test antibody, essentially as described in Example 1, but with different cysteine mutations resulting in different target maximum drug-to-antibody ratios (DARs), (4, 6, or 8). The resulting conjugates were analyzed by HIC-UHPLC (TSKgel Butyl-NPR column) and PLRP-HPLC (MAbPAC RP) to determine the degree of conjugation.
[0246] result [Table 4] Conclusion: The Gly5 version offered a far superior conjugation profile compared to the PEG5 version. *****
[0247] Several publications are referenced above to more fully describe and disclose the disclosures and conditions of the technical fields to which the present invention may relate herein. Each of the references referenced herein is incorporated herein by reference in its entirety.
Claims
1. An antibody-drug conjugate having structure (1), 【Chemistry 1】 During the ceremony, Cell binding agents such as AB and antibodies, n is an integer in the range of 5 to 8. L 1 However, it is a linker, L 2 However, it is a linker, L 3 However, it is a linker, a, b, and c are independently 0 or 1. Is Z a conjugation group obtained by a metal-free click reaction, thiol ligation, or transglutaminase-mediated transamidation? Alternatively, Z is absent, a and b are 0, the N-terminus of polyglycine is directly bound to AB in the absence of the saltase recognition sequence motif, and D is the drug payload. An antibody-drug conjugate in which x is an integer in the range of 1 to 8.
2. D is exatecan, and optionally, the drug linker is cleaved under cellular conditions, resulting in the following equation (D 1 ): 【Chemistry 2】 (D 1 The antibody-drug conjugate according to claim 1, which can release exatecan having )
3. L 3 The antibody-drug conjugate according to claim 1 or 2, comprising a cathepsin-cleavable peptide or a legmine-cleavable peptide.
4. L 3 but, 【Transformation 3】 It has structure (1a), 【Chemistry 4】 During the ceremony, AB is a cell-binding agent such as an antibody, n is an integer in the range of 5 to 8. L 1 However, it is a linker, L 2 is a linker, L 3a However, it is a linker, a, b, and d are independently 0 or 1. Is Z a conjugation group obtained by a metal-free click reaction, thiol ligation, or transglutaminase-mediated transamidation? Alternatively, Z is absent, a and b are 0, and the N-terminus of polyglycine is directly conjugated to AB in the absence of the saltase recognition sequence motif. D is the drug payload, p is an integer in the range of 1 to 5. Each R 11 However, independently, they are amino acid side chains, An antibody-drug conjugate according to any one of the prior claims, wherein x is an integer in the range of 1 to 8.
5. L 3 The antibody-drug conjugate according to any one of the prior claims, comprising a self-sacrificing group.
6. Having structure (1b), 【Transformation 5】 During the ceremony, AB is a cell-binding agent such as an antibody, n is an integer in the range of 5 to 8. L 1 However, it is a linker, L 2 However, it is a linker, a and b are independently 0 or 1. Is Z a conjugation group obtained by a metal-free click reaction, thiol ligation, or transglutaminase-mediated transamidation? Alternatively, Z is absent, a and b are 0, and the N-terminus of polyglycine is directly bound to AB in the absence of the saltase recognition sequence motif. D is the drug payload, p is an integer in the range of 0 to 5. Each R 11 However, independently, they are amino acid side chains, A is a 5 or 6-membered aromatic or heteroaromatic ring that has been optionally substituted. R 21 However, H, R 22 , C(O)OH, and C(O)R 22 Selected from, R 22 However, C 1 -C 24 (hetero)alkyl group, C 3 -C 10 (hetero)cycloalkyl group, C 2 -C 10 (hetero)aryl group, C 3 -C 10 Alkyl (hetero)aryl groups and C 3 -C 10 (Hetero)arylalkyl group, wherein the group is optionally substituted with O, S, and NR 23 Optionally interrupted by one or more heteroatoms selected from R 23 However, independently, hydrogen and C 1 -C 4 Selected from the group consisting of alkyl groups, The antibody-drug conjugate according to claim 4 or 5, wherein x is an integer in the range of 1 to 8.
7. Peptide (NH-CR 11 -CO) Each occurrence of p is Val-Cit, Glu-Val-Cit, Val-Ala, Val-Lys, Val-Arg, Aclys-Val-Cit, Aclys-Val-Ala, Glu-Val-A la, Asp-Val-Ala, Phe-Gly, Phe-Cit, Phe-Ala, Phe-Lys, Phe-Arg, Ala-Lys, Leu-Cit, Ile-Cit, Trp-Cit, Ala-A An antibody-drug conjugate according to any one of the prior claims, comprising la-Asn, Asn-Asn, Ala-Asn, and Lys, optionally selected from Val-Cit, Glu-Val-Cit, Val-Ala, Glu-Val-Ala, Val-Lys, Phe-Gly, Phe-Cit, Phe-Ala, Phe-Lys, Ala-Ala-Asn, optionally selected from Val-Cit or Val-Ala.
8. The antibody-drug conjugate according to any one of the prior claims, wherein the conjugating group Z can be obtained by a metal-free click reaction and comprises a triazole moiety, or group Z can be obtained by thiol ligation and comprises a succinimidyl ring or a ring-opened succinic acid amide derivative thereof.
9. Having structure (1c), 【Transformation 6】 Z, L 2 , L 3 D, b, c, n, and x are as defined in any one of the prior claims, e is an integer in the range of 0 to 20. Su is a monosaccharide, G is the monosaccharide portion, GlcNAc is the N-acetylglucosamine portion. Fuc is the fucose portion, An antibody-drug conjugate according to any one of the prior claims, wherein m is 0 or 1.
10. L 2 The antibody-drug conjugate according to any one of the prior claims, but without a (poly)ethylene glycol linker.
11. L 2 However, - (CR 1 R 2 )y-,-(CR 1 R 2 )y-C(O)-, and -C(O)-(CR 1 R 2 ) Selected from y - C(O) - where y is an integer in the range of 0 to 6, and one or more CR 1 R 2 However, NR 1 It can be optionally replaced by R 1 and R 2 However, independently, H and R 2a , C(O)OH, and C(O)R 2a Selected from, R 2a However, C was replaced by an arbitrary choice. 1 -C 6 (hetero)alkyl group, C 3 -C 10 (hetero)cycloalkyl group, C 6 -C 10 (hetero)aryl group, C 7 -C 14 Alkyl (hetero)aryl group, and C 7 -C 14 An antibody-drug conjugate according to any one of the prior claims, selected from (hetero)arylalkyl groups.
12. A process for synthesizing an antibody-drug conjugate according to any one of claims 1 to 11, wherein the process comprises: (i) Structure AB-((L 1 ) a -F)x modified antibody, in the formula, Cell binding agents such as AB and antibodies, L 1 However, it is a linker, a is 0 or 1, F is a click probe that can react with Q in a metal-free click reaction, or a thiol or its precursor, or an acyl donor that can react with Q in transglutaminase-mediated transamidation. Modified antibodies where x is an integer in the range of 1 to 8, A linker-drug construct according to structure (5), 【Transformation 7】 During the ceremony, Q is a click probe capable of performing a metal-free click reaction, or a thiol-reactive probe, or an acyl-acceptor probe capable of reacting with acyl donor F in transglutaminase-mediated transamidation. L 2 , L 3 , reacted with a linker-drug construct such that D, n, b, and c are as defined in any one of the prior claims, A process comprising forming an antibody-drug conjugate, wherein the drug is covalently bound to the antibody via a conjugate group Z formed by a metal-free click reaction between Q and F, by thiol ligation between Q and F, or by transglutaminase-mediated transamidation between Q and F.
13. The process according to claim 12, wherein the click probe Q includes a cyclic alkyne portion, a cyclic alkene portion, or a tetrazine portion.
14. The process according to claim 12, wherein the thiol-reactive probe Q includes or is a maleimide moiety.
15. The process according to any one of claims 12 to 14, wherein the click probe F is selected from the group consisting of azides, tetrazines, triazines, nitrones, nitrile oxides, nitrile imines, diazo compounds, ortho-quinones, dioxothiophenes, cydonones, alkynes, and cyclic alkenes, preferably the click probe F is an azide moiety and / or the click reaction is a 1,3-dipolar cycloaddition or a (4+2) cycloaddition, or F is a thiol and / or the thiol ligation is a Michael addition or nucleophilic substitution.
16. AB-((L 1 )a-F)x is due to structure (6), 【Transformation 8】 In the formula, F and x are defined in any one of the prior claims, e is an integer in the range of 0 to 10. Su is a monosaccharide, G is the monosaccharide portion, GlcNAc is the N-acetylglucosamine portion. Fuc is the fucose portion, The process according to any one of claims 12 to 15, wherein m is 0 or 1.
17. A linker-drug construct according to structure (5), 【Chemistry 9】 During the ceremony, Q is a click probe capable of performing a metal-free click reaction, or a thiol-reactive probe, or an acyl-acceptor probe capable of reacting with acyl donor F in transglutaminase-mediated transamidation. L 2 , L 3 A linker-drug construct in which D, n, b, and c are as defined in any one of the prior claims.
18. The linker-drug construct according to claim 17, wherein the click probe Q comprises a cyclic alkyne moiety, a cyclic alkene moiety, or a tetrazine moiety.
19. The linker-drug construct according to claim 17, wherein the thiol-reactive probe Q includes or is a maleimide moiety.
20. A pharmaceutical composition comprising an antibody-drug conjugate according to any one of claims 1 to 11 and a pharmaceutically acceptable carrier.
21. An antibody-drug conjugate according to any one of claims 1 to 11, for use in the treatment of subjects requiring treatment.
